

Sonoma Biotherapeutics

Protocol: SBT777101-01

eCRF Completion Guidelines



A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis

# **VERSION HISTORY**

| VERSION DATE | VERSION NUMBER | AUTHOR            | SUMMARY  |
|--------------|----------------|-------------------|--|
| 13-Sep-2023  | 1.0            | T.Nguyen          | Initial Draft  |
|              |                |                   | Revised draft following sponsor comments Updated Data Coordinator contact Added screenshots  |
|              |                |                   | Added General Instructions section 8 – Navigating the Audit Trail  |
|              |                |                   | Sponsor Approved Version 1.0   |
| 07-Mar-2024  | 2.0            | T.Nguyen / S.Hall | Updated Schedule of Assessments with administrative changes Updated fields on Eligibility form per sponsor Updated Adverse Event form to rearrange fields "Was the event related to a trial procedure?", "If yes, specify:", and "Did this Adverse Event lead to study discontinuation?"   |
|              |                |                   | Added new field "Were any abnormal results clinically significant?" and updated screen note on <i>Local Laboratory</i> – <i>Urinalysis</i> form  |
|              |                |                   | Dynamics - Updated dynamics for which forms appear if subject meets all Screening Eligibility, Inclusion Not Met/Exclusion Criteria Met, Pre-Treatment Visits 2, Local Laboratory - Pregnancy, Local Laboratory - Post Menopause, Early Termination added dynamics for Infusion Related Reactions  Adverse Events - Removed fields "ASTCT CRS grade:" and "ASTCT ICANS grade:". Added new fields: "Start time (24 hour clock):", "End time (24 hour clock):", "Check this box if this event is related to CRS:", and "Check this box if this event is related to Neurotoxicity/ICANS:". Updated CTCAE Grade to be required field and added dynamics note. Added N/A option for Grade. Updated "Infusion Related Reaction" field to "Infusion Related Reaction (IRR):" Updated "Check this box if this event is related to CRS:" to "Is this event related to CRS:" and "Check this box if this event related to Neurotoxicity/ICANS:" to "Is the event ongoing?", "End date:", "End time (24 hr clock):". Added new fields "Associated Adverse Event #1:", "Associated Adverse Event #2:", "Associated Adverse |
|              |                |                   | Event #3:" and "ASTCT CRS grade:"  Neurotoxicity/ICANS Signs and Symptoms - Removed fields: "Corresponding Primary Adverse Event Number:", "Start date:", "Start Time (24 hr clock):", "Is the event ongoing?", "End date:", "End time (24 hr clock):". Added new fields "Associated Adverse Event #1:", "Associated Adverse Event #2:",   |

| VERSION DATE | VERSION NUMBER | AUTHOR           | SUMMARY  |
|--------------|----------------|------------------|--|
|              |                |                  | "Associated Adverse Event #3:" and "ASTCT ICANS grade:"  Apheresis Eligibility (Pre-Treatment) - Added new fields "Date of Screen Failure at Apheresis:", "Primary Reason for Screen Failure at Apheresis:", and "Primary Reason for Screen Failure at Apheresis Other, Specify:"  Pre-Treatment/Pre-Infusion Eligibility - Updated field "Did the subject meet all pre-infusion eligibility?" to "Did the subject meet all pre-infusion eligibility and approved for enrollment into the treatment period of the study?". Added new field "Date of Screen Failure at Pre-Treatment:". Update dynamics notes  Eligibility - Added new fields "Date of Screen Failure at Screening:", "Primary Reason for Screen Failure at Screening:", "Primary Reason for Screen Failure at Screening Other, Specify:"  Apheresis - Removed all Second and Other Apheresis fields. Updated Initial Apheresis fields to removed "Initial". Added new fields to capture reason Apheresis not done and not successful. Added Start time and End time fields for Apheresis.  Infusion Related Reactions - New form added GATE form - Any AE/CM/PR - Added new field "Were there any Infusion Related Reactions (IRR)?"  General instructions – Updated section 2 #8 on SF limited casebooks, adding additional CRFs to SF casebook  Vital Signs – Changed BMI to note that it is a read-only field  Adverse Events – Added guidelines for AE changes in severity when an event is not a pre-existing condition |
| 03-Jul-2024  | 3.0            | T.Nguyen, S.Hall | Added note to section 2 to clarify subject ID is unique and cannot be reused  Tobacco Use – added new form and dynamics for form  Any Medical History – Added new field "Does the subject have any past and/or concomitant use of tobacco?", removed "abuse" language, and Updated "Does the subject have any past and/or concomitant" to match the SU screen note  Alcohol and Drug Use – updated field text, removed "abuse" language and updated screen note to "prior to signing informed consent"  Apheresis Eligibility (Pre-Treatment) and Pre-Treatment/Pre-Infusion Eligibility – renamed forms   |

| VERSION DATE | VERSION NUMBER | AUTHOR | SUMMARY  |
|--------------|----------------|--------|--|
|              |                |        | Added Prior Rheumatoid Arthritis Treatment Medication, Local Laboratory - HIV Screening, and Next Visit - Pre-Treatment Updated dynamics for various forms and added dynamics for new forms Physical Examination – Form was retired and replaced by Physical Examination 1 form Medical History - Rheumatoid Arthritis – Updated various field names Updated names for Apheresis Eligibility (Pre- Treatment) and Pre-Treatment/Pre-Infusion Eligibility forms Adverse Events – updated verbiage about SAE's and various other places to mirror changes in HS CCG's Prior & Concomitant Treatments/Medications – updated verbiage about medications and dosing to match HS CCG's Apheresis – removed second apheresis fields   |
| 09-Oct-2024  | 4.0            | S.Hall | Removed all COVID information from forms  Dynamics – Added PE1CS dynamics, updated dynamic for Next Visit – Pre-Treatment to appear for all subjects  Adverse Events – Added "Possibly" option to Is this event related to CRS and Neurotoxicity/ICANS? Fields  12-Lead Electrocardiogram - Triplicate – Updated QtcF Average field to be calculated and read only Synovitis Assessment – Updated Was a Synovitis Assessment field to "Was a Synovitis Assessment for the purpose of biopsy performed?" and Which Joints? field with "are potential sites for biopsy".  Apheresis – Added new fields re:Cell Manufacturing Health Assessment Questionnaire - Disability Index – Removed highest score, highest adjusted score fields per sponsor request  Medical History – Removed CTCAE v5.0 to Severity |
| 24 Apr 2025  | 5.0            | CHell  | Local Laboratories - Clinical Chemistry 1 and 2, Hematology 1 and 2, Lipid – Removed some units from fields per sponsor request.  Sponsor Approved version 4.0  Medical History – Updated "Was there a change in this  |
| 24-Apr-2025  | 5.0            | S.Hall | event since screening before pre-infusion?" and "Severity Grade before Pre-Infusion" to clarify that it is the pre-infusion visit that is being referred to Vital Signs – Oxygen Saturation – Added new form Immune Effector Cell-Associated Encephalopathy (ICE) Score – updated ICE score fields to be read only and calculated fields Added Navigation Tree Icon Guide to general instructions  |

| VERSION DATE | VERSION NUMBER | AUTHOR | SUMMARY  |
|--------------|----------------|--------|--|
|              |                |        | Apheresis – Added new field "Reason Cell Manufacturing Not Successful Other, Specify:"  Health Assessment Questionnaire – Disability Index – Updated AIDS DAEW/HRGA and HELP DAEW/HRGA fields to include "None" option  Medical History – Rheumatoid Arthritis – Added fields to capture ACPA titer/units  C-Reactive Protein/Erythrocyte Sedimentation Rate – Updated ESR field to remove decimal.  Rheumatoid Arthritis Serology Testing (RA) – Added new field  Local Lab – Hematology 1 and 2 – Added additional lab units for certain analytes  Joint Count Assessments – Removed visible visit dynamics from (66) fields.  Adverse Event – Added note for action taken. Added note about post infusions event actions being "Not applicable". Added note to IRR field. |
|              |                |        | Synovitis Assessment – Update gate field to "Was Synovitis Assessment performed using ultrasound?" and removed "How was the assessment", "If Other assessment", "Was synovitis confirmed?", "Which joints", and "other" fields. Added grading fields Medical History – Removed severity grade fields per sponsor request Adverse Event – Added CRS and ICANs grade fields. Updated DLT field to remove " (Dose Escalation only, first 28 days of treatment)?".  CRS Signs and Symptoms and Neurotoxicity/ICANS Signs and Symptoms – Removed grade field  |
|              |                |        | MRI Assessment – Added new repeating form and dynamics  12-Lead Electrocardiogram – Triplicate – Added "or sitting" to the position fields  Inclusion Not Met/Exclusion Not Met – Added options  28-31 for "What was the identifier". Updated visible dynamics for "What was the identifier" field.  Adverse Events – Added new field "Is this event an AESI?"  Sponsor Approved Version 5.0   |

### ELECTRONIC CASE REPORT FORM COMPLETION GUIDELINES

These electronic Case Report Form (eCRF) Completion Guidelines are organized to provide general instructions that apply to all eCRFs. If you have any questions regarding completion of the eCRFs, please contact your Clinical Research Associate (CRA) or the Medpace Data Coordinator.

#### CONTACT INFORMATION

The Medpace EDC Help Desk supports users with technical issues, such as system login failures.

#### **EDC Help Desk**

Phone: 1-800-730-5779, call and follow prompts to reach EDC Help Desk

or

Email: EDCHelp@medpace.com

Contact the Data Coordinator or Data Manager for study specific questions related to the EDC system, forms and queries.

#### **Data Manager**

Shuta (Mike) Wu Phone: +1-513-706-7117 Email: S.Wu1@Medpace.com

#### **Data Coordinators**

Trang Nguyen
Phone: +1-513-579-9911 x 25377
Email: T.Nguyen5@Medpace.com

Sophia Hall Phone: +1-513-579-9911 x 27124 Email: S.Hall@Medpace.com

# **CONTENTS**

| VERSION HISTORY   | 2  |
|---|----|
| ELECTRONIC CASE REPORT FORM COMPLETION GUIDELINES                       | 6  |
| CONTACT INFORMATION   | 6  |
| CONTENTS  | 7  |
| GENERAL INSTRUCTIONS  | 10 |
| 1. Electronic Data Capture System and Access                            | 10 |
| 2. Adding A Subject In EDC  | 10 |
| 3. Navigating EDC and Completing eCRFs                                  | 12 |
| 4. Data Entry and Query Guidelines                                      | 14 |
| 5. Data Entry Conventions   | 15 |
| 6. Unscheduled Visits   | 15 |
| 7. Principal Investigator Signature and Serious Adverse Event Reporting | 15 |
| 8. Navigating the Audit Trail   | 16 |
| SCHEDULE OF ASSESSMENTS   | 17 |
| DYNAMICS AND TRIGGERS   | 21 |
| DATE OF VISIT   | 25 |
| INFORMED CONSENT/DEMOGRAPHICS   | 26 |
| ELIGIBILITY   | 28 |
| INCLUSION NOT MET/EXCLUSION CRITERIA MET                                | 30 |
| PRE-TREATMENT AND PRE-INFUSION ELIGIBILITY                              | 31 |
| ANY MEDICAL HISTORY   | 33 |
| MEDICAL HISTORY   | 34 |
| MEDICAL HISTORY - RHEUMATOID ARTHRITIS                                  | 35 |
| RHEUMATOID ARTHRITIS SEROLOGY TESTING (RA)                              | 40 |
| PRIOR RHEUMATOID ARTHRITIS TREATMENT MEDICATION 1                       | 42 |
| ALCOHOL AND DRUG USE  | 44 |
| TOBACCO USE   | 45 |
| VITAL SIGNS   | 47 |
| VITAL SIGNS - OXYGEN SATURATION   | 50 |
| PHYSICAL EXAMINATION 1  | 51 |
| PHYSICAL EXAMINATION 1 - CLINICAL FINDINGS                              | 53 |
| 12-LEAD ELECTROCARDIOGRAM - TRIPLICATE                                  | 54 |
| CHEST X-RAY   | 57 |
| SYNOVITIS ASSESSMENT  | 58 |
| SYNOVIAL BIOPSY AND FLUID COLLECTION                                    | 59 |
| APHERESIS ELIGIBILITY (PRE-TREATMENT)                                   | 61 |

| APHERESIS  | 63  |
|--|-----|
| LOCAL LABORATORY - SEROLOGICAL AND TUBERCULOSIS TESTS      | 65  |
| LOCAL LABORATORY - PREGNANCY                               | 67  |
| LOCAL LABORATORY - POST MENOPAUSE                          | 69  |
| LOCAL LABORATORY - COAGULATION                             | 70  |
| LOCAL LABORATORY-HEMATOLOGY1                               | 72  |
| LOCAL LABORATORY-HEMATOLOGY 2                              | 75  |
| LOCAL LABORATORY-HIV SCREENING                             | 78  |
| LOCAL LABORATORY-CLINICAL CHEMISTRY1                       | 79  |
| LOCAL LABORATORY-CLINICAL CHEMISTRY 2                      | 82  |
| LOCAL LABORATORY - CREATININE CLEARANCE/EGFR               | 85  |
| LOCAL LABORATORY - URINALYSIS                              | 86  |
| LOCAL LABORATORY-LIPID TESTS                               | 88  |
| C-REACTIVE PROTEIN/ERYTHROCYTE SEDIMENTATION RATE          | 91  |
| JOINT COUNT ASSESSMENTS                                    | 92  |
| VISUAL ANALOG SCALE (VAS)                                  | 94  |
| IMMUNE EFFECTOR CELL-ASSOCIATED ENCEPHALOPATHY (ICE) SCORE | 96  |
| HEALTH ASSESSMENT QUESTIONNAIRE - DISABILITY INDEX         | 99  |
| FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY - FATIGUE | 107 |
| PHARMACOKINETIC BLOOD SAMPLES                              | 116 |
| PBMC IMMUNOGENICITY  | 117 |
| SERUM ANTI-DRUG ANTIBODY                                   | 118 |
| PLASMA/SERUM EXPLORATORY BIOMARKERS                        | 119 |
| PBMC EXPLORATORY BIOMARKERS                                | 120 |
| REPLICATION COMPETENT LENTIVIRUS                           | 121 |
| MRI ASSESSMENTS  | 122 |
| NEXT VISIT – PRE-TREATMENT                                 | 123 |
| SBT777101 ADMINISTRATION                                   | 124 |
| NEXT VISIT   | 129 |
| GATE FORM – ANY AE/CM/PR                                   | 130 |
| ADVERSE EVENTS   | 131 |
| CRS SIGNS AND SYMPTOMS                                     | 140 |
| NEUROTOXICITY/ICANS SIGNS AND SYMPTOMS                     | 142 |
| INFUSION RELATED REACTIONS                                 | 144 |
| PRIOR & CONCOMITANT TREATMENTS/MEDICATIONS                 | 145 |
| PRIOR & CONCOMITANT PROCEDURES                             | 149 |
| GATE-MARKERS   | 150 |

| MARKERS OF INFLAMMATION        | 151 |
|--------------------------------|-----|
| DEATH DETAILS                  | 154 |
| RECONSENT                      | 155 |
| EARLY TERMINATION/END OF STUDY | 156 |


#### GENERAL INSTRUCTIONS

### 1. Electronic Data Capture System and Access

- Data will be entered in electronic Case Report Forms (eCRFs) in the ClinTrak® Electronic Data Capture (EDC) system via the following URL: <a href="https://clintrakedc.medpace.com">https://clintrakedc.medpace.com</a>
- Requests for access are made via ClinTrak® Systems Access Request Management (ARM) via the following URL: https://clintrak.medpace.com/ClinTrakARM/Account/Login
- All non-read only users must be trained prior to being granted access to the study within the EDC system.
- Training will be performed and documented within the EDC system. The training video links are within EDC and based on role. Users who have previously completed the required trainings are not required to repeat training.
- Training video link(s) will appear after initial login. Training acknowledgement will be required before accessing a study portal.
- Once training has been acknowledged, you may find your training certificate by accessing the 'My Profile' tab and clicking 'Print Training Certificate'. Save a copy of your training certificate with your study related documents.

### 2. Adding A Subject In EDC


- The 9-character sequential subject number (**S01-XYY, ZZZ**), where S01 is the unique protocol identifier number, X is the country code, YY is the site number (01-99 assigned chronologically) and ZZZ is the subject identifier (001, 002, 003,...). Each subject ID is unique and cannot be reused.
- Subjects will be manually entered into EDC:



- 1. Click on the Data Entry tab located at the top of ClinTrak EDC.
- 2. Click the site name in the navigation tree.
- 3. Click +Add New Subject.
- 4. The Site field will be pre-populated with the assigned site number.
- 5. Enter the 3-digit subject identification number.
- 6. Click Save Subject to add the subject.
- 7. If enter correctly, the complete subject number for subject <u>001</u> at site <u>01</u> in the <u>US</u> should display as <u>S01-101-001</u> in EDC.


8. If for any reason the subject ID needs to be updated, select the subject in the navigation tree, click the **Edit Subject Key** button, update the **Subject** field, and provide a reason for the update.

Note: Each subject ID is unique and cannot be reused. If a subject is a re-screen, the subject will receive a new subject ID.



- Screen Failures will have a limited casebook. The following eCRFs will need to be completed:
  - o Date of Visit
  - Informed Consent/Demographics
  - Eligibility
  - Inclusion Not Met/Exclusion Criteria Met
  - GATE form Any AE/CM/PR (only record medications and procedures if used for treatment in an adverse event for Screen Failures)
  - Adverse Events
- Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened. Subjects may be rescreened up to 2 times, if deemed appropriate by the Principal Investigator. All screening assessments that led to screen failure must be repeated for rescreening.

### 3. Navigating EDC and Completing eCRFs




- Navigate between subjects, visits, and eCRFs via the Navigation Tree, located in the left panel of the Data Entry tab
- In the Navigation Tree, use the arrows () to locate the form on which you want to enter data. Click on the form name. The form will appear in the window on the right side of the screen.
- Once data entry is complete, click the green Save button in the lower left side of the screen. If data is entered
  into the form in error, click the red Cancel All button.
- If data entry needs to be updated after saved, select the field, enter new data, and click the green **Save** button in the lower left side of the screen.
- To correct the order of forms in the Navigation Tree, select the Reset button (2) located at the top of the Navigation Tree window.
- If eCRF data is entered in error and needs to be cleared, click the **Reset Form** button located in the lower left side of the screen, enter a **Reason** for clearing data on the form, and click **Confirm**.
- Repeating forms: Multiple records can be added for repeating forms, such as Medical History, Adverse Events, and Prior and Concomitant Medications.

For reference, below is the navigation tree icon guide



#### Adding Repeating Forms



- 1. Locate the Gate Form (e.g. Any Adverse Events?). This is typically a 'Yes' or 'No' question. Once 'Yes' is selected and saved, the first Repeating Form will appear in the Navigation Tree the corresponding CRF will be made available for data entry.
- 2. Click on the newly added form. The entry screen will appear in the window on the right side of the screen.
- If additional forms are needed, click the +Add Another button, which appears in the lower left corner once the first form is saved.
- Additional forms can also be added by clicking on the form name (e.g. Adverse Events) and clicking Add Additional Form


#### **Deleting Repeating Forms**

- 1. If the data on a repeating form is entered in error and needs to be cleared, click the **Delete** button located on the lower left side of the screen, enter a **Reason** for deleting the record, and click **Confirm**.
- 2. If a repeating form is deleted in error and needs to be restored, click the **Restore Form** button located on the lower left-hand side of the screen, enter a **Reason** for restoring, and click **Confirm**.
- If a subject terminates early from the study, do not enter any data in the eCRFs for events that were not performed.
- The eCRF Completion Guidelines locate in the Documents tab of the study portal.



Protected health information (PHI) such as name, initials, full date of birth (as country specific regulations apply),
 etc. must not be entered into the CRF or be used in query responses.

### 4. Data Entry and Query Guidelines



- Data entry is expected to be completed in EDC within 5 business days of each visit.
- Queries should be reviewed and responded to within 5 days of the query generation.
- Query and data entry timelines can be shortened at study specific milestones, upon specific request, or during lock.
- All queries in a state of 'Open' require resolution from the site. To locate all 'Open' queries:
  - 1. Click on the Status tab located at the top of ClinTrak EDC. A table is provided listing all queries in an 'Open' state.
  - 2. Clicking on the ( ) icon at the end of each row takes the user directly to the entry screen where the query is located.
  - 3. A Query Status Indicator is located next to each field on the entry screen showing the status of the queries associated with that field. Red text and (!) icon on a field indicate an open query that requires a response from the site coordinator.
- All changes and query responses made to the eCRFs require a reason for change, which will be tracked via the audit trail in the eCRF.
  - 1. When data changes are made, a Change Reason-Respond box will open asking for the reason for change.
  - 2. When responding to a query, a Query Response box will open asking for the response to the query.
  - 3. Once all necessary data changes are made and/or query responses are provided on the form, select **Save** in the lower left corner of the form.
  - 4. A complete history of changes and query responses can be viewed in the audit trail by clicking (2) next to the field.

### 5. Data Entry Conventions

- Avoid using abbreviations.
- The date format is **DD/MMM/YYYY**. All Date fields will require a complete date unless 'UNK' is listed in the drop-down select box. For partial dates, a minimum of the year is required.
- All times must be entered in a 24-hour clock format. Where applicable, 'UNK' will be available if an unknown
  time is permitted. If only the hour is known, and the minutes are not, please enter the hour as appropriate and
  choose 'UNK' for the minutes.
- Rounding convention: For decimal values, round to the nearest expected decimal place (e.g., 50.67 kg should be entered as 50.7 kg for a field in which only one decimal place is expected, per protocol. 50.679 kg should be entered as 50.68 kg for a field in which two decimal places are expected, per protocol, etc.).
- Drop-down select boxes will contain all possible responses for that field. You may select only one response from a drop-down select box. If 'Other' is selected from a drop-down select box, the system may allow entry into a corresponding 'Specify' text box, when applicable.

#### 6. Unscheduled Visits

- Every subject added to a study is automatically provided with one optional Unscheduled (UNS) visit.
  - 1. If applicable, complete the associated Date of Visit eCRF.
  - 2. Click on the Unscheduled Visit 1 header in the Navigation Tree.
  - 3. All available forms for an Unscheduled visit will appear in the window on the right side of the screen. Click **Add Form** next to each form required for the UNS visit. The added form(s) will appear in the Navigation Tree under the Date of Visit eCRF.
- To add additional Unscheduled visits, click on the subject ID in the tree and click Add next to Unscheduled under Create Additional Events.

## 7. Principal Investigator Signature and Serious Adverse Event Reporting

- The Principal Investigator (PI) must electronically sign all subjects' Case Report Form books for database lock. If further corrections or changes are required after the Investigator signs, the system will automatically un-sign the case book and the Investigator will be required to re-sign.
- All Serious Adverse Events (SAEs) must be reported to Medpace Clinical Safety group and Sonoma
  Biotherapeutics through EDC within 24 hours of knowledge, if available. If it is not possible to access the EDC
  system within the required timeframe, send an email with the SAE to Medpace Safety at Medpacesafetynotification@medpace.com or call the Medpace SAE reporting line: +1-800-730-5779, dial 3 or +1-513-5799911, dial 3 and fax/email the completed paper SAE form to Medpace within 24 hours of knowledge.
  - PI electronic signature is required for SAEs; the signature should occur as soon as possible after the SAE is reported and when updates are made.

### 8. Navigating the Audit Trail

- Navigation of the audit trail is explained in the EDC training video.
- The audit trail can be viewed by data item or at the form level. Click the item history icon next to the specific data item or generate form history report(s) from the visit/event screen to view the audit trail.



Note: History Icon highlighted above

> The audit trail shows the actions performed for that data field, such as data entry, data changes, and data cleaning activities (e.g., SDV and queries). User and timestamp are displayed for each action.

## **SCHEDULE OF ASSESSMENTS**

Note: Form availability shown is for Enrollment through Week 4 (Safety Follow-Up).

| Note: Form availability shown i                  | 3 IOI LIIIOII       | inent tinou              | gii week 4               | (Salety I Of                               | 10w-0p).  |       |      |               |      |       |             |             |             |
|--|---------------------|--------------------------|--------------------------|--|---|-------|------|---------------|------|-------|-------------|-------------|-------------|
|  | Screening<br>Period | Pre-Treatn               | nent Period              | Reassessmen<br>1, and each ne              | eatment<br>at X Period (X =<br>ew period adds<br>)† | Safet |      |               |      |       |             |             | Safety Foll |
| † Indicates Repeating Visit or Form<br>Visit:    | Screening Visit     | Pre-Treatment 1          | Pre-Treatment 2          | Pre-Treatment 1                            | Pre-Treatment 2                                     | 1     | Week | 1 4/5         | 7    | We    | ek 2        | Week 3      | Week 4      |
| Day  Visit Name (How visits will appear ins EDC) | Screening           | Pre-Treatment<br>Visit 1 | Pre-Treatment<br>Visit 2 | Pre-Treatment<br>Reassessment X<br>Visit 1 | Pre-Treatment<br>Reassessment X<br>Visit 2          | W1D1  | W1D2 | 4/5<br>W1D4/5 | W1D7 | W2D11 | 14<br>W2D14 | 21<br>W3D21 | 28<br>W4D28 |
| Visit Name in EDC Extract                        | SCR                 | PRT1                     | PRT2                     | Pre-Treatment<br>Reassessment X<br>Visit 1 | Pre-Treatment<br>Reassessment X<br>Visit 2          | W1D1  | W1D2 | W1D4/5        | W1D7 | W2D11 | W2D14       | W3D21       | W4D28       |
| Visit Window (Days)                              | -56 to -42          | -41 to -11               | -10 to -4                | -41 to -11                                 | -10 to -4   |       |      |               | ±1   | ±1    | ±2          | ±2          | ±2          |
| Sheet Form*                                      |                     |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Date of Visit                                    | X                   | X                        | X                        | X  | X   | X     | X    | Х             | Х    | X     | X           | X           | X           |
| Informed Consent/Demographics                    | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Eligibility                                      | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Inclusion Not Met/Exclusion Criteria Met†        | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Any Medical History                              | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Medical History†                                 | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Alcohol and Drug Use                             | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Tobacco Use†                                     | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Medical History - Rheumatoid Arthritis           | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Prior Rheumatoid Arthritis Treatment Medication† | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Prior Rheumatoid Arthritis Treatment Medication  | Х                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Vital Signs                                      | X                   |                          | X                        |  | Х   | Х     | Х    | X             | Х    | Х     | X           | Х           | Х           |
| Vital Signs - Oxygen Saturation                  | X                   |                          | X                        |  | X   | X     |      |               |      |       |             |             |             |
| Physical Examination 1                           | X                   |                          | X                        |  | X   | X     | X    | Х             | Х    | Х     | Х           | Х           | X           |
| Physical Examination 1 - Clinical Findings†      | X                   |                          | X                        |  | X   | X     | X    | X             | X    | X     | X           | X           | X           |
| 12-Lead Electrocardiogram -Triplicate            | X                   |                          | X                        |  | X   | Α     |      |               | X    |       | X           |             |             |
| Chest X-Ray                                      | ^                   |                          | X                        |  | X   |       |      |               | ^    |       | ^           |             |             |
| Synovitis Assessment                             |                     |                          | X                        |  | X   |       |      |               |      |       |             |             | X           |
| Synovial Biopsy and Fluid Collection             |                     |                          | X                        |  | X   |       | 1    |               |      |       |             |             | X           |
| Apheresis Eligibility (Pre-Treatment)            | X                   | Х                        |                          | Х  |   |       |      |               |      |       |             |             |             |
| Apheresis  |                     | X                        |                          | X  |   |       |      |               |      |       |             |             |             |
| Local Laboratory - HIV Screening                 | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Local Laboratory - Serological and Tuberculosis  |                     |                          |                          |  |   |       | 1    |               |      |       |             |             |             |
| Tests  | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Local Laboratory - Pregnancy                     | Х                   |                          | Х                        |  | X   | X     |      |               |      |       |             |             |             |
| Local Laboratory - Post Menopause                | X                   |                          |                          |  |   |       |      |               |      |       |             |             |             |
| Local Laboratory - Coagulation                   | X                   |                          | Х                        |  | X   |       |      |               |      |       |             |             |             |
| Local Laboratory - Hematology 1                  | X                   |                          | Х                        |  | X   | ·     | X    | X             | X    | X     | X           | X           | X           |
| Local Laboratory - Hematology 2                  | X                   |                          | X                        |  | Х   |       | X    | X             | Х    | X     | X           | X           | X           |
| Local Laboratory - Clinical Chemistry 1          | X                   |                          | X                        |  | X   |       | X    | X             | Х    | X     | X           | X           | X           |
| Local Laboratory - Clinical Chemistry 2          | X                   |                          | X                        |  | X   |       | X    | X             | Х    | X     | X           | X           | X           |
| Local Laboratory - Creatinine Clearance/eGFR     | X                   |                          | ļ                        |  |   |       |      |               |      |       |             |             | <b></b>     |
| Local Laboratory - Urinalysis                    | X                   |                          | X                        |  | X   |       |      |               |      |       |             |             |             |

# SCHEDULE OF ASSESSMENTS (CONTINUED)

Note: Form availability shown is for Enrollment through Week 4 (Safety Follow-Up)

|   | Screening<br>Period | Pre-Treatn                   | Dro. I reatment Derion       |                     | eatment<br>t X Period (X =<br>w period adds |              |          |                |              |          |  |          | Safety Foll |
|---|---------------------|------------------------------|------------------------------|---------------------|---|--------------|----------|----------------|--------------|----------|--|----------|-------------|
| † Indicates Repeating Visit or Form<br>Visit:                   | Screening<br>Visit  | Pre-<br>Treatment 1          | Pre-<br>Treatment 2          | Pre-<br>Treatment 1 | Pre-<br>Treatment 2                         |              | Week     |                |              |          | ek 2   | Week 3   | Week 4      |
| Day   |                     |                              |                              |                     |   | 1            | 2        | 4/5            | 7            | 11       | 14   | 21       | 28          |
| Visit Name (How visits will appear ins EDC)                     | Screening           | Pre-<br>Treatment<br>Visit 1 | Pre-<br>Treatment<br>Visit 2 |                     | Pre-<br>Treatment<br>Reassessmen            | <b>₩1</b> D1 | ₩1D2     | ₩104/5         | <b>₩</b> 1D7 | ₩2D11    | ₩2D14  | ₩3D21    | ₩4D28       |
| Visit Name in EDC Extract                                       | SCR                 | PRT1                         | PRT2                         |                     | Pre-<br>Treatment<br>Reassessmen            | <b>₩1</b> 01 | ₩1D2     | ₩104/5         | <b>₩</b> 1D7 | ₩2D11    | ₩2D14  | ₩3D21    | ₩4D28       |
| Visit Window (Days)   | -56 to -42          | -41 to -11                   | -10 to -4                    | -41 to -11          | -10 to -4                                   |              |          |                | ±1           | ±1       | ±2   | ±2       | ±2          |
| Sheet Form*   |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |
| Local Laboratory – Lipid Tests                                  |                     |                              | ×                            |                     | ×   |              |          |                |              |          |  |          |             |
| C-Reactive Protein/Erythrocyte                                  | ×                   |                              | l ×                          |                     | x   |              | l x      |                | ×            |          | ×  | ×        | ×           |
| Sedimentation Rate  |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |
| Rheumatoid Arthritis Serology Testing (RA)                      | u                   |                              |                              |                     |   |              |          |                |              |          |  |          | <del></del> |
| Joint Count Assessments   | <u> </u>            |                              | ×                            |                     | X   |              |          |                |              |          | X  |          | X           |
| Visual Analog Scale (VAS) Immune Effector Cell-Associated       | ×                   |                              | ×                            |                     | ×   |              |          |                |              |          | ×  |          | X           |
| Encephalopathy (ICE) Score†                                     |                     |                              | ×                            |                     | ×   | ×            | X        | ×              | X            | X        | X  | ×        | ×           |
| Health Assessment Questionnaire - Disability                    |                     |                              |                              |                     |   |              |          |                |              |          |  |          | <del></del> |
| Index   | ×                   |                              | ×                            |                     | ×   |              |          |                |              |          | ×  |          | ×           |
| Functional Assessment of Chronic Illness                        |                     |                              | ×                            |                     | ×   |              |          |                |              |          |  |          |             |
| Therapy – Fatigue   |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |
| Pharmacokinetic Blood Samples                                   |                     |                              | X                            |                     | X   |              | X        | X              | X            | X        | X  | X        | ×           |
| PBMC Immunogenicity   |                     |                              | ×                            |                     | ×   |              |          |                |              |          |  |          | X           |
| Serum Anti-drug Antibody  | U                   |                              | X                            |                     | X   |              |          |                | U            |          |  | U        | X           |
| Plasma/Serum Exploratory Biomarkers                             | ×                   |                              | ×                            |                     | ×   |              | ×        | <del>   </del> | X            |          | ×  | ×        | ×           |
| PBMC Exploratory Biomarkers                                     | ×                   |                              | ×                            |                     | ×   |              | ×        | X              | X            | ×        | ×  | ×        | ×           |
| Replication Competent Lentivirus                                |                     |                              | ×                            |                     | ×   |              |          |                |              |          |  |          |             |
| Pre-Treatment/Pre-Infusion Eligibility SBT777101 Administration |                     |                              | ×                            |                     | ×   | X            | 1        |                |              |          |  |          | $\vdash$    |
| Next Visit  |                     |                              |                              |                     |   |              | l x      | ×              | ×            | ×        | ×  | ×        | ×           |
| Next Visit - Pre-Treatment                                      |                     | ×                            |                              | ×                   |   | n            | <u> </u> |                | - ^          | <u> </u> | <del>  ^</del>                                   | <u> </u> |             |
| GATE form - Any AE/CM/PR  |                     | - "                          |                              |                     |   |              |          |                |              |          | <del>                                     </del> |          | $\vdash$    |
| Adverse Events†   |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |
| CRS Signs and Symptoms†   |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |
| Neurotoxicity/ICANS Signs and Symptoms†                         |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |
| Infusion Related Reactions†                                     |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |
| Prior & Concomitant Treatments/Medications†                     |                     |                              |                              |                     |   |              |          |                |              |          |  |          | $\perp$     |
| Prior & Concomitant Procedures†  MRI Assessments†               |                     | -                            |                              |                     |   |              |          |                |              |          |  |          |             |
| GATE - Markers  |                     | <del> </del>                 |                              |                     |   |              | 1        |                |              |          | <del> </del>                                     |          | $\vdash$    |
| Markers of Inflammation†  |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |
| Early Termination/End of Study                                  |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |
| Death Details   |                     | 1                            |                              |                     |   |              | 1        |                |              |          |  |          |             |
| Reconsent   |                     |                              |                              |                     |   |              |          |                |              |          |  |          |             |

# SCHEDULE OF ASSESSMENTS (CONTINUED)

Note: Form availability shown is for Week 6 (Safety Follow-Up) through Early Termination/End of Study visits including Unscheduled visits.

| Visit Name (How visits will appear ins EDC)   W6042   W8056   W10070   W12084   W180126   W240168   W360252   End of Termination   Summary   Markers of Inflammation   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   NIA   Unscheduled Visit   W180126   W240168   W360252   EOS   ET   NIA   W180126   W180 |   | ow-Up  |       |        |        |         |         |         |                    | Early<br>Termination |         |     |                          |
|--|---|--------|-------|--------|--------|---------|---------|---------|--------------------|----------------------|---------|-----|--------------------------|
| Visit Name in EDC Extract  | Visit   | Week 6 |       |        |        |         |         |         | 48/End of<br>Study |                      | Summary |     | Unscheduled <sup>†</sup> |
| Visit Window (Days)   12   12   12   13   17   17   17   17   17   17   17   | Visit Name (How visits will appear ins EDC)     | W6D42  | W8D56 | W10D70 | W12D84 | W18D126 | W24D168 | W36D252 |                    |                      | Summary |     | Unscheduled Visits X     |
| Sheet   Form:  | Visit Name in EDC Extract                       | W6D42  | W8D56 | W10D70 | W12D84 | W18D126 | W24D168 | W36D252 | EOS                | ET                   | N/A     | N/A | Unscheduled Visits X     |
| Date of Visit  | Visit Window (Days)                             | ±2     | ±2    | ±2     | ±3     | ±7      | ±7      | ±7      | ±7                 |                      |         |     |                          |
| Informed Consent/Demographics  |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Eligibility  |   | X      | X     | X      | X      | X       | X       | X       | X                  | X                    |         |     | X                        |
| Inclusion Not Met/Exclusion Criteria Met†  |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Any Medical History  |   | -      |       |        |        |         |         |         |                    |                      |         |     |                          |
| Medical History†   |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Alcohol and Drug Use   |   | -      |       |        |        |         |         |         |                    |                      |         |     |                          |
| Tobacco Use†   Medical History - Rheumatoid Arthritis  |   | -      |       |        |        |         |         |         |                    |                      |         |     |                          |
| Medical History - Rheumatoid Arthritis   |   |        |       | -      |        |         |         |         |                    |                      |         |     |                          |
| Prior Rheumatoid Arthritis Treatment Medication  |   | -      |       |        |        |         |         |         |                    |                      |         |     |                          |
| Prior Rheumatoid Arthritis Treatment Medication   11   | ·   |        |       | -      |        |         |         |         |                    |                      |         |     |                          |
| 11   | ·   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Vital Signs - Oxygen Saturation  |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Physical Examination 1   | Vital Signs                                     | Х      | Х     | Х      | Х      | Х       | Х       | Х       | Х                  | Х                    |         |     | Х                        |
| Physical Examination 1   | Vital Signs - Oxygen Saturation                 |        |       |        |        |         |         |         |                    |                      |         |     | X                        |
| Physical Examination 1 - Clinical Findings†  |   | Х      | Х     | Х      | Х      | Х       | Х       | Х       | Х                  | Х                    |         |     |                          |
| 12-Lead Electrocardiogram -Triplicate  | Physical Examination 1 - Clinical Findings†     |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Chest X-Ray   Synovitis Assessment   X   |   | _ ~    |       |        |        |         |         |         |                    |                      |         |     |                          |
| Synovial Biopsy and Fluid Collection   |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Apheresis Eligibility (Pre-Treatment)  | Synovitis Assessment                            |        |       |        | Х      |         |         |         |                    | Х                    |         |     |                          |
| Apheresis   Local Laboratory - HIV Screening   X   | Synovial Biopsy and Fluid Collection            |        |       |        | Х      |         |         |         |                    | X                    |         |     | X                        |
| Cocal Laboratory - HIV Screening   | Apheresis Eligibility (Pre-Treatment)           |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Local Laboratory - Serological and Tuberculosis  | Apheresis                                       |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Tests  | Local Laboratory - HIV Screening                |        |       |        |        |         |         |         |                    |                      |         |     | X                        |
| Local Laboratory - Pregnancy   | Local Laboratory - Serological and Tuberculosis |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Local Laboratory - Post Menopause  |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Local Laboratory - Coagulation         X <th< td=""><td></td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td></td><td>X</td><td>X</td><td></td><td></td><td>X</td></th<>  |   |        |       |        | X      | X       | X       |         | X                  | X                    |         |     | X                        |
| Local Laboratory - Hematology 1         X <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>   |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Local Laboratory - Hematology 2         X <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>   |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Local Laboratory - Clinical Chemistry 1         X  |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| Local Laboratory - Clinical Chemistry 2 X X X X X X X X X X X X X X X X X X  |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
|  |   |        |       |        |        |         |         |         |                    |                      |         |     |                          |
| II coal I charatary, Creatining Clearance/oCED   |   | X      | Х     | X      | Х      | X       | Х       | Х       | Х                  | X                    |         |     | X                        |
| Local Laboratory - Creatinine Clearance/eGFR Local Laboratory - Urinalysis  X X X X X  |   |        | v     | -      |        |         |         |         | V                  | V                    |         |     |                          |

# SCHEDULE OF ASSESSMENTS (CONTINUED)

Note: Form availability shown is for Week 6 (Safety Follow-Up) through Early Termination/End of Study visits including Unscheduled visits.

| Process   Proc   |   | оw-Up  |          |        |        |        |        |        |                    | Early<br>Termination |     |     |                          |
|--|---|--|----------|--------|--------|--------|--------|--------|--------------------|----------------------|-----|-----|--------------------------|
| Visit Name (How visits will appear in EDC)   Visit Name in EDC Extract   Visit Vindow (Days)   22   42   42   43   47   47   47   47   47   47   47  | Visit:                                      |  |          |        |        |        |        |        | 48/End<br>of Study |                      |     |     | Unscheduled <sup>†</sup> |
| Visit Name in EUL Extract   Visit Vindov (Days)   12   12   12   12   13   17   17   17   17   17   17   17  |   |  |          |        |        | ₩18D12 | ₩24D16 | ₩36D25 | End of             |                      |     |     |                          |
| Sheet  | Visit Name in EDC Extract                   | ₩6D42  | ₩8D56    | ₩10D70 | ₩12D84 |        |        |        | EOS                | ET                   | N/A | N/A |                          |
| Local Laboratory - Lipid Tests   | Visit Window (Days)                         | ±2   | ±2       | ±2     | ±3     | ±7     | ±7     | ±7     | ±7                 |                      |     |     |                          |
| C-Reactive ProteinEptotrocyte  | Sheet Form"                                 |  |          |        |        |        |        |        |                    |                      |     |     |                          |
| Sedimentation Rate   |   |  |          |        |        |        |        |        | X                  |                      |     |     |                          |
| Sedimentation Hate   |   | Ιx   | l x      | l x    | ×      | ×      | l x    | l x    | ×                  | l x                  |     |     | ×                        |
| Joint Count Assessments  |   | ļ  |          |        |        |        |        |        |                    |                      |     |     |                          |
| Visual Analog Scale (VAS)  | 3, 3, ,                                     |  |          |        |        |        |        |        |                    |                      |     |     |                          |
| Immune Effector Cell-Associated  |   |  |          |        |        |        |        |        |                    |                      |     |     | X                        |
| Encephalopathy (ICE) Score†  |   | ┞  | X        |        | X      | X      | X      |        | X                  | ×                    |     |     |                          |
| Index  | Encephalopathy (ICE) Score†                 | ×  | ×        | ×      | ×      | ×      | ×      | ×      | X                  | ×                    |     |     | ×                        |
| Therapy - Fatigue  | Index                                       |  | ×        |        | X      | ×      | ×      |        | ×                  | ×                    |     |     |                          |
| PBMC   Immunogenicity  |   |  |          |        |        | ×      | ×      |        | ×                  | ×                    |     |     |                          |
| Serum Anti-drug Antibody   | Pharmacokinetic Blood Samples               | ×  |          | X      |        | X      | X      | X      |                    |                      |     |     |                          |
| Plasma/Serum Exploratory Biomarkers  |   |  |          |        |        |        |        |        |                    |                      |     |     |                          |
| PBMC Exploratory Biomarkers  |   | Ļ  |          |        |        |        |        |        |                    |                      |     |     |                          |
| Replication Competent Lentivirus   |   |  |          |        |        |        |        |        |                    |                      |     |     |                          |
| Pre-Treatment/Pre-Infusion Eligibility SBT777101 Administration Next Visit Next Visit Next Visit Pre-Treatment GATE form - Any AE/CM/PR Adverse Events† CRS Signs and Symptoms† Neurotoxicity/ICANS Signs and Symptoms† Infusion Related Reactions† Prior & Concomitant Treatments/Medications† Prior & Concomitant Treatments/Medications† Prior & Concomitant Procedures† MBI Assessments† GATE - Markers Markers of Inflammation† Early Termination/End of Study  | PBMC Exploratory Biomarkers                 | ×  | X        | X      |        | X      |        | X      |                    | ×                    |     |     |                          |
| SBT777101 Administration   Next Visit  |   |  |          |        | X      |        | X      |        | X                  |                      |     |     | X                        |
| Next Visit — Pre-Treatment  SATE form — Any AE/CM/PR Adverse Events†  CRS Signs and Symptoms†  Neurotoxicity/ICANS Signs and Symptoms†  Infusion Related Reactions†  Prior & Concomitant Treatments/Medications†  Prior & Concomitant Procedures†  MRI Assessments†  SATE form — Any AE/CM/PR  AND — A |   |  |          |        |        |        |        |        |                    |                      |     |     |                          |
| Next Visit - Pre-Treatment GATE form - Any AE/CM/PR Adverse Events† CRS Signs and Symptoms† Neurotoxicity/ICANS Signs and Symptoms† Infusion Related Reactions† Prior & Concomitant Treatments/Medications† Prior & Concomitant Procedures† MRI Assessments† GATE - Markers Markers of Inflammation† Early Termination/End of Study  |   | <b>—</b> —                                       |          |        | 0      | 0      | 0      | 0      |                    |                      |     |     |                          |
| GATE form - Any AE/CM/PR   |   | <del>                                     </del> | <u> </u> | _ ×    | ×      | X      | ×      | X      |                    |                      |     |     |                          |
| Adverse Events†  CRS Signs and Symptoms†  Neurotoxicity/ICANS Signs and Symptoms†  Infusion Related Reactions†  Prior & Concomitant Treatments/Medications†  Prior & Concomitant Procedures†  MRI Assessments†  GATE - Markers  Markers of Inflammation†  Early Termination/End of Study   |   |  |          |        |        |        |        |        |                    |                      | -   |     |                          |
| CRS Signs and Symptoms†  Neurotoxicity/ICANS Signs and Symptoms†  X  Prior & Concomitant Treatments/Medications†  Prior & Concomitant Treatments/Medications†  Neurotoxicity/ICANS Signs and Symptoms†  X  Prior & Concomitant Treatments/Medications†  Neurotoxicity/ICANS Signs and Symptoms†  X  Prior & Concomitant Treatments/Medications†  Neurotoxicity/ICANS Signs and Symptoms†  X  Neurotoxicity/ICANS Signs and Symptoms*  X  Neurotox |   |  |          |        |        |        |        |        |                    |                      |     |     |                          |
| Infusion Related Reactions†  |   |  |          |        |        |        |        |        |                    |                      |     |     |                          |
| Infusion Related Reactions†  | Neurotoxicity/ICANS Signs and Sumptoms†     |  |          |        |        |        |        |        |                    |                      | ×   |     |                          |
| Prior & Concomitant Treatments/Medications†  Prior & Concomitant Procedures†  MRI Assessments†  GATE - Markers  Markers of Inflammation†  Early Termination/End of Study   |   |  |          |        |        |        |        |        |                    |                      |     |     |                          |
| MRI Assessments† X X S S S S S S S S S S S S S S S S S   | Prior & Concomitant Treatments/Medications† |  |          |        |        |        |        |        |                    |                      | ×   |     |                          |
| GATE - Markers X X X X X X X X X X X X X X X X X X X   |   |  |          |        |        |        |        |        |                    |                      |     |     |                          |
| Markers of Inflammation† Study |   |  |          |        |        |        |        |        |                    |                      | X   |     |                          |
| Early Termination/End of Study   |   |  |          |        |        |        |        |        |                    |                      |     |     |                          |
|  | -   |  |          |        |        |        |        |        |                    |                      | · · | ×   |                          |
| Death Details  |   |  |          |        |        |        |        |        |                    |                      |     |     |                          |
|  | Death Details Reconsent†                    | -  |          |        |        |        |        |        |                    |                      |     |     |                          |

### **DYNAMICS AND TRIGGERS**

The only forms visible upon the initial entering of the patient in EDC are contained within the Screening and Summary folders. In the Screening folder, the only forms available are the Date of Visit, Informed Consent/Demographics, and Eligibility. In the Summary folder, the only form available is GATE form - Any AE/CM/PR.

Additional visits and/or forms may appear based on responses to existing form fields. An outline of the forms/visits expected to display based on certain responses is provided below. The "Trigger Form" is the form that is already available that contains the trigger question. The "Trigger Question" is the field that, depending on the response to it, will trigger additional forms/visits. The "Target Form" is the form that will become available based on the response to the trigger question. The response that will trigger the target form will be shown in [] brackets.

| <u>Trigger Form</u> | Trigger Form Question  | <u>Target Form</u>  |
|---------------------|--|---|
| Eligibility         | Did the subject meet all screening eligibility? [YES]  | Screening folder: Any Medical History, Vital Signs, Vital Signs – Oxygen Saturation, Physical Examination 1, 12- Lead Electrocardiogram -Triplicate, Local Laboratory - Serological and Tuberculosis Tests, Local Laboratory – Coagulation, Local Laboratory - Hematology (1&2), Local Laboratory - Clinical Chemistry (1&2), Local Laboratory – Urinalysis, Health Assessment Questionnaire - Disability Index, Local Laboratory - Creatinine Clearance/eGFR, Plasma/Serum Exploratory Biomarkers, PBMC Exploratory Biomarkers, Medical History - Rheumatoid Arthritis, Synovitis Assessment, C-Reactive Protein/Erythrocyte Sedimentation Rate, Joint Count Assessments, Visual Analog Scale (VAS)  Summary folder: Early Termination/End of Study, Death Details, Reconsent  Markers of Inflammation folder: GATE - Markers Unscheduled Visits |
| Eligibility         | Primary Reason for Screen Failure at Screening phase: [FAILURE TO MEET TREATMENT ELIGIBILITY REQUIREMENTS] | Inclusion Not Met/Exclusion Criteria Met  |

# **DYNAMICS (CONTINUED)**

| <u>Trigger Form</u>                                   | Trigger Form Question  | Target Form/Visit                          |
|---|--|--|
| Fliaibilia, AND Aubanais                              | Did the publicat most all assessing  |  |
| Eligibility AND Apheresis Eligibility (Pre-Treatment) | Did the subject meet all screening eligibility? [YES] AND Protocol version subject consented to [5.0] OR Did the subject meet all screening eligibility? [YES] AND Protocol version subject consented to [6.0 or above] AND Did the subject meet all apheresis eligibility? [YES] at Screening | Pre-Treatment Visits 1                     |
| Next Visit - Pre-Treatment                            | Is the subject continuing to the Pre-<br>Treatment/Pre-Infusion visit OR will the<br>subject be reassessed for apheresis at a<br>later date?" [Pre-Treatment/Pre-Infusion]<br>@ Pre-Treatment 1 OR Pre-Treatment<br>Reassessment X Visit 1 where X = 1, 2,<br>3                                | Pre-Treatment Visits 2                     |
| Informed<br>Consent/Demographics AND<br>Eligibility   | Sex [FEMALE] Subject child bearing potential [POTENTIALLY ABLE TO BEAR CHILD] AND Did the subject meet all screening eligibility? [YES]  | Local Laboratory - Pregnancy               |
| Informed<br>Consent/Demographics AND<br>Eligibility   | Sex [FEMALE] Subject child bearing potential [POST-MENOPAUSAL] AND Did the subject meet all screening eligibility? [YES]   | Local Laboratory - Post Menopause          |
| Any Medical History                                   | Has the subject experienced any past and/or concomitant diseases? [YES]  | Medical History                            |
| Any Medical History                                   | Does the subject have any past and/or concomitant use of alcohol and/or drugs within the previous year? [YES]  | Alcohol and Drugs Use                      |
| Any Medical History                                   | Does the subject have any past and/or concomitant use of tobacco? [YES]  | Tobacco Use                                |
| GATE form - Any AE/CM/PR                              | Did the subject experience any adverse events? [YES]   | Adverse Events                             |
| GATE form - Any AE/CM/PR                              | Did the subject take any prior or concomitant medications? [YES]   | Prior & Concomitant Treatments/Medications |
| GATE form - Any AE/CM/PR                              | Did the subject have any prior or concomitant procedures? [YES]  | Prior & Concomitant Procedures             |
| GATE form - Any AE/CM/PR                              | Did the subject experience any adverse events? [YES] Were any of the adverse events related to CRS? [YES]  | CRS Signs and Symptoms                     |
| GATE form - Any AE/CM/PR                              | Did the subject experience any adverse events? [YES] Were any of the adverse event related to Neurotoxicity? [YES]   | Neurotoxicity Signs and Symptoms           |


# **DYNAMICS (CONTINUED)**

| <u>Trigger Form</u>                       | Trigger Form Question   | Target Form/Visit  |  |
|---|---|--|--|
| GATE form - Any AE/CM/PR                  | Did the subject experience any adverse events? [YES] Were there any Infusion Related Reactions? [YES]   | Infusion Related Reactions   |  |
| GATE - Markers                            | Were Markers of Inflammation assessed? [YES]  | Markers of Inflammation  |  |
| Pre-Treatment/Pre-Infusion<br>Eligibility | Did the subject meet all pre-infusion eligibility and approved for enrollment into the treatment period of the study? [YES]   | Week 1 Day 1 (W1D1)  |  |
| Next Visit - Pre-Treatment                | Is the subject continuing to the Pre-<br>Treatment/Pre-Infusion visit OR will the<br>subject be reassessed for apheresis at a<br>later date? [Apheresis reassessment] | Pre-Treatment Reassessment X Visit 1where X = 1, 2, 3  |  |
| Pre-Treatment/Pre-Infusion<br>Eligibility | Will the subject be eligible for reassessment at a later date? [YES]  | Pre-Treatment Reassessment X Visit 2 where X = 1, 2, 3   |  |
| Next Visit                                | Is the subject continuing to the next visit? [YES]  | Next visit of Week X added (e.g. If "Yes" at W2D11, W2D14 is added) where Y = 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36           |  |
| Next Visit                                | Is the subject continuing to the next visit? [NO]   | Early Termination visit  |  |
| Next Visit                                | Is the subject continuing to the next visit? [YES] at Week 36 Day 252 (W36D252)   | End of Study visit   |  |
| Pre-Treatment/Pre-Infusion Eligibility    | Will the subject be eligible for reassessment at a later date? [NO] at Pre-treatment 2 or any Pre-Treatment Reassessment X Visit 2 where X = 1, 2, 3,                 | Early Termination visit  |  |
| Eligibility                               | Did the subject meet all screening eligibility? [Yes] AND Protocol version subject consented to [5.0]   | Synovial Biopsy and Fluid Collection @Screening  |  |
| Eligibility                               | Protocol version subject consented to [6.0 or above]  | Synovial Biopsy and Fluid Collection<br>@Pre-Treatment 2 or any Pre-Treatment<br>Reassessment X Visit 2 where X = 1, 2,<br>3 |  |
| Eligibility                               | Did the subject meet all screening eligibility? [Yes] AND Protocol version subject consented to [6.0 or above]  | Apheresis Eligibility (Pre-Treatment) @Screening   |  |
| Eligibility                               | Protocol version subject consented to [5.0 or above]  | Apheresis Eligibility (Pre-Treatment) @Pre-Treatment 1   |  |
| Eligibility                               | Did the subject meet all screening eligibility? [Yes] AND Protocol version subject consented to [6.0 or above]  | Local Laboratory - HIV Screening @SCR  |  |

# **DYNAMICS (CONTINUED)**

| <u>Trigger Form</u>       | Form Trigger Form Question Target Form/Visit  |   |
|---------------------------|---|---|
| Eligibility               | Did the subject meet all screening eligibility? [Yes] AND Protocol version subject consented to [5.0]   | Prior Rheumatoid Arthritis Treatment Medication   |
| Eligibility               | Did the subject meet all screening eligibility? [Yes] AND Protocol version subject consented to [6.0 or above]  | Prior Rheumatoid Arthritis Treatment Medication 1 |
| Physical Examination 1    | Were there any abnormal and clinically significant findings or changes since the last exam? [Yes]   | Physical Examination 1 – Clinical Findings        |
| Eligibility AND Reconsent | Did the subject meet all screening eligibility? [Yes] AND Protocol version subject consented to [7.0 or above] OR Did the subject meet all screening eligibility? [Yes] AND Protocol version subject which subject reconsented under [7.0 or above] | MRI   |

### DATE OF VISIT



Did the visit occur?

Indicate visit status from the drop-down list:

- No
- Yes, completed
- · Yes, partially completed

Note: If "No" is selected, provide a response in the "Reason visit did not occur:" field

Date of visit:

Provide the date of visit in the DD/MMM/YYYY format. A complete date is required.


How was the visit conducted?

Indicate how the visit was conducted by selecting from the drop-down list:

- In Person
- Telephone Call
- Remote Audio

Remote Audio Video

#### INFORMED CONSENT/DEMOGRAPHICS



Date informed consent signed by subject:

Record the date the subject signed the Informed Consent in the DD/MMM/YYYY format. A complete date is required.

Did the subject consent to future research of Blood, CAR Treg Cells, Synovial Tissue, and Synovial Fluid samples? Indicate if the subject consented to future research of Blood, CAR Treg Cells, Synovial Tissue, and Synovial Fluid samples by selecting No or Yes.

Date of birth:

Record the **date of birth** of the subject in the **DD/MMM/YYYY** format. A complete date is required unless country specific requirements prohibit a full date of birth to be recorded. At least a year is required for entry.

Sex at birth:

Select the subject's sex at birth from the drop-down list:

- Female
- Male
- Undifferentiated
- Unknown

## **INFORMED CONSENT/DEMOGRAPHICS (CONTINUED)**

Subject childbearing potential:

Indicate if the **subject is of childbearing potential** by selecting from the drop-down list:

- Post-menopausal
- · Surgically sterile
- Potentially able to bear child

Note: This field is only enabled if "Sex:" is "Female" or "Undifferentiated"

Note: If "Post-menopausal" is selected, complete the Local Laboratory - Post

**Menopause** eCRF

Note: If "Potentially able to bear child" is selected, complete the Local Laboratory

- Pregnancy eCRF

Ethnicity:

Indicate the subject's **Ethnicity** by selecting from the drop-down list:

- Hispanic or Latino
- Not Hispanic or Latino
- Not Reported
- Unknown


Race (Select all that apply):

Select all applicable box(es) for the subject's applicable Race(s):

- American Indian or Alaska Native
- Asian
- Black or African American
- Native Hawaiian or Other Pacific Islander
- White
- Other

Note: If the subject's race is not an option listed above, select "Other" and specify the race in the "If Other, specify" field

#### **ELIGIBILITY**



Did the subject meet all screening eligibility?

Select No or Yes.

Note: If "No" is selected, an Inclusion Not Met/Exclusion Criteria Met eCRF will appear. Please complete the form to indicate the criterion that the patient did not meet

Protocol version subject consented to:

Select the **protocol version** the subject enrolled under from the drop-down list:

• 5.0

• 8.0

• 6.0

• 9.0

• 7.0

10.0

Cohort

Select the **cohort** the patient enrolled in from the drop-down list:

- Dose Level 1
- Dose Level 2
- Dose Level 3
- Other

Note: If "Other" is selected, provide a response in the "Cohort, Other Specify" field

Date of Screen Failure at Screening:

Record the date of Screen Failure at Screening phase in the DD/MMM/YYYY format. A complete date is required.

# **ELIGIBITY (CONTINUED)**

Primary Reason for Screen Failure at Screening:

Select the **primary reason** from the drop-down list:

- ADVERSE EVENT
- FAILURE TO MEET TREATMENT ELIGIBILITY REQUIREMENTS
- STUDY TERMINATED BY SPONSOR
- WITHDRAWAL BY SUBJECT
- OTHER

Note: If "Other" is selected, specify the reason in the "Primary Reason for Screen  $\,$ 

Failure at Screening Other, Specify:" field

Is this subject a rescreen?


Select No or Yes.

If yes, specify subject's previous Subject ID:

If the subject is a rescreened subject, provide the **previous subject number** in the **S01-XYY**, **ZZZ** format, where X is the country code, YY is the site number and ZZZ is the subject identifier.

Note: This field is only enabled if "Is this subject a rescreen?" is "Yes"

### INCLUSION NOT MET/EXCLUSION CRITERIA MET



Record any Inclusion criteria not met or Exclusion criteria met per protocol. This is a repeating form (multiple records can be added). Both Inclusion and Exclusion criteria can be captured if applicable.

#### Please enter a record for each criterion not met.

What was the category of the criterion?

Record whether the **criterion** that this patient did not meet was **Inclusion** or **Exclusion**.

What was the identifier of the criterion?

Select the **identifier of the criterion** from the dropdown list:

| • | 1  | • | 11 | • | 21 |
|---|----|---|----|---|----|
| • | 2  | • | 12 | • | 22 |
| • | 3  | • | 13 | • | 23 |
| • | 4  | • | 14 | • | 24 |
| • | 5  | • | 15 | • | 25 |
| • | 6  | • | 16 | • | 26 |
| • | 7  | • | 17 | • | 27 |
| • | 8  | • | 18 | • | 28 |
| • | 9  | • | 19 | • | 29 |
| • | 10 | • | 20 | • | 30 |
|   |    |   |    | • | 31 |

Note: Values 1-19 will only be available if the category is **Inclusion**, and values 1-31 will be available if the category is **Exclusion** 

#### PRE-TREATMENT AND PRE-INFUSION ELIGIBILITY

An Eligibility eCRF is available for completion at **Screening**, **Pre-Treatment Visit 2**, and **Pre-Treatment Reassessment X Visit 2** (where **X = 1, 2, 3,...**) visits.



Did the subject meet all preinfusion eligibility and approved for enrollment into the treatment period of the study? Select **No** or **Yes**.

Date of eligibility assessment:

Record the **date of eligibility assessment** in the **DD/MMM/YYYY** format. A complete date is required.

Primary reason:

Select the **primary reason** from the dropdown list:

- ADVERSE EVENT
- MEDICAL HISTORY
- CONCOMITANT MEDICATION
- CLINICALLY SIGNIFICANT RESULTS FROM LABS OR ASSESSMENTS
- DAS28 less than 3.2
- OTHER

Note: This field is only enabled if "Did the subject meet all pre-infusion eligibility and approved for enrollment into the treatment period of the study?" is "No"

Note: If "Adverse Event" is selected, provide an Adverse Event number in the "Primary Adverse Event" field

Note: If "Other" is selected, provide a response in the "Primary reason, Other specify:" field

## PRE-TREATMENT AND PRE-INFUSION ELIGIBITY (CONTINUED)

Will the subject be eligible for reassessment at a later date?

Indicate if the **subject will be eligible for reassessment at a later date** by selecting from the drop-down list:

- No
- Yes
- Not applicable at this time

Note: This field is only enabled if "Did the subject meet all pre-infusion eligibility and approved for enrollment into the treatment period of the study?" is "No"

Date of eligibility failure:

Record the **date of eligibility failure** in the **DD/MMM/YYYY** format. A complete date is required

This field is only enabled if "Will the subject be eligible for reassessment at a later date?" is "No"

### **ANY MEDICAL HISTORY**



Has the subject experienced any past and/or concomitant diseases?

Select **No** or **Yes**. A response is required.

Note: If Yes is selected, a Medical History eCRF will appear for completion

Does the subject have any past and/or concomitant use of alcohol and/or drugs within 1 year prior to signing informed consent?

Select No or Yes. A response is required.


Note: If **Yes** is selected, an **Alcohol and Drugs Use** eCRF will appear for completion

Does the subject have any past and/or concomitant use of tobacco?

Select No or Yes. A response is required.

Note: If Yes is selected, a Tobacco Use eCRF will appear for completion

#### **MEDICAL HISTORY**



This is a repeating form (multiple records can be added)

Medical history will include but is not limited to clinically significant diseases, surgeries, cancer history (including prior cancer therapies and procedures), inflammatory/autoimmune disease.

Event/diagnosis:

In the field provided, record the event or diagnosis.

- · Record only one event or diagnosis per record.
- Conditions/diagnoses with an onset on or after the Day 1 visit or baseline condition that worsens thereafter should be reported on the Adverse Events eCRF.
- If applicable, please specify the exact location of the body concerned by the Medical History (i.e. Left, Right or Bilateral). Also, if necessary, enter if the Medical History is "chronic" or "acute".
- When applicable, report the stage/grade of the event (ex: for retinopathy, nephropathy, tumors etc.).

<u>Note:</u> Please do not record Rheumatoid Arthritis as a medical history event since it is the disease under study.

Start date:

Record the **start date** of the event/diagnosis in the **DD/MMM/YYYY** format.

Note: A year is required for start date. "**Unknown**" is an available selection for Day

and Month

Ongoing?

Select **No** or **Yes** to indicate if the event/diagnosis is currently **ongoing**.

Note: If the medical history changes/updates from ongoing to resolved during

the study, update this field accordingly


End date:

Record the end date of the event/diagnosis in the DD/MMM/YYYY format.

Note: This field is only enabled if "Ongoing?" is "No". A year is required for end date.

"Unknown" is an available selection for Day and Month

#### MEDICAL HISTORY - RHEUMATOID ARTHRITIS



Initial diagnosis date:

Record the date of the initial diagnosis in the DD/MMM/YYYY format.

Note: "Unknown" is an available option for the day and month of the initial diagnosis, however a year is required

Date of Rheumatoid factor (RF) test:

Record the date of Rheumatoid factor (RF) test in the DD/MMM/YYYY format. A complete date is required.

Note: A year is required for start date. "**Unknown**" is an available selection for Day and Month

Rheumatoid factor (RF) status

Indicate the Rheumatoid factor (RF) status by selecting from the drop-down list:

- Negative
- Positive
- Unknown

Rheumatoid factor (RF) titer (IU/mL)

Record the Rheumatoid factor (RF) titer at screening in IU/mL.

Note: This field is only enabled if "Rheumatoid factor (RF) status" is "Positive"

Date of Anti-Citrullinated Protein Antibody (ACPA) test:

Record the date of Anti-Citrullinated Protein Antibody (ACPA) test in the DD/MMM/YYYY format. A complete date is required.

Note: A year is required for start date. "**Unknown**" is an available selection for Day and Month

Anti-Citrullinated Protein Antibody (ACPA) status

Indicate the **Anti-Citrullinated Protein Antibody (ACPA) status** by selecting from the drop-down list:

- Negative
- Positive
- Unknown

## MEDICAL HISTORY- RHEUMATOID ARTHRITIS (CONTINUED)

Anti-Citrullinated Protein Antibody (ACPA) titer at Screening Record the Anti-Citrullinated Protein Antibody (ACPA) titer at screening.

Note: This field is only enabled if "Anti-Citrullinated Protein Antibody (ACPA) status" is "Positive"

**ACPA Unit** 

Select the unit for ACPA from the drop-down list:


- Units/UCU
- EU/mL
- Other

Note: This field is only enabled if "Anti-Citrullinated Protein Antibody (ACPA) status" is "Positive"

Note: If "Other" is selected, provide a response in the "ACPA Unit Other, Specify:" field

## PRIOR RHEUMATOID ARTHRITIS TREATMENT MEDICATION

Only populates for subjects enrolled in protocol version 5.0



# PRIOR RHEUMATOID ARTHRITIS TREATMENT MEDICATION (CONTINUED)

This is a repeating form (multiple records can be added).

Please record all DMARD treatments (including conventional synthetic, biologic and targeted synthetic) used since RA diagnosis. Do not record any pain relief medications or corticosteroids on this form.

Please record one drug treatment per line. If a combo treatment, please record each drug in the combo separately.

Treatment/Medication Name: Enter one treatment/medication into the text box provided.

Note: If treatment/medication is a combination, record each drug separately

**Type of treatment:** Select the **type of treatment** from the drop-down list:

csDMARD (Methotrexate, Hydroxychloroquine)

bDMARD or biosimilar (Adalimumab, Golimumab, Infliximab,...)

• tsDMARD (Baricitinib, Filgotinib, Tofacitinib, Upadacitinib)

Steroids

Investigational Agent

Other

Note: If "Other" is selected, provide a response in the "If Type of treatment is

Other, Specify:" field

Start date: Record the start date of the treatment/medication in the DD/MMM/YYYY format.

Note: A year is required for start date. "Unknown" is an available selection for Day

and Month

Ongoing? Select No or Yes to indicate if the treatment/medication is currently ongoing.

<u>Note:</u> If the treatment/medication changes/updates from ongoing to resolved during or at the end of the study, update this field accordingly to avoid overlapping records.

End date: Record the end date of the treatment/medication in the DD/MMM/YYYY format.

Note: This field is only enabled if "Ongoing?" is "No". A year is required for end date.

"Unknown" is an available selection for Day and Month

## PRIOR RHEUMATOID ARTHRITIS TREATMENT MEDICATION (CONTINUED)

**Dose:** Record the numeric **dose** of the treatment/medication taken in the field provided. If

dose of an ongoing medication changes, add and end date to prior record and add a

new record for the new dosage.

**Unit:** Select the **unit** of the dose taken from the drop-down list:

• mg

mg/kg

gram

mg/m^2

Other

Note: If "Other" is selected, provide a response in the "If Unit is other, specify:"

field

**Frequency:** Select the **frequency** of the treatment/medication from the drop-down list:

Once Daily QD

Twice Daily BID

Three Times Daily TID

4 Times a Day QID

Once weekly or Every Week

As Needed PRN

Once a Month

Every 6 Months

Other

Note: If "Other" is selected, provide a response in the "If Frequency is other,

specify:" field

**Route:** Select the **route** of the treatment/medication from the drop-down list:

Oral PO

Intramuscular IM

Intra-articular IA

Intravenous IV

Subcutaneous SC

Other

Note: If "Other" is selected, provide a response in the "If Route is other, specify:"

field. For injections, start date and stop date are usually the same.

**Reason for Discontinuing** 

Select the reason for discontinuing from the drop-down list:

Completed course of therapy

• Inadequate response

Toxicity

Other

Note: This field is only enabled if "Ongoing?" is "No"

Note: If "Other" is selected, provide a response in the "If Reason for Discontinuing

is other, specify:" field

# RHEUMATOID ARTHRITIS SEROLOGY TESTING (RA)



Date of Rheumatoid factor (RF) test:

Record the date of Rheumatoid factor (RF) test in the DD/MMM/YYYY format. A complete date is required.

Note: A year is required for start date. "**Unknown**" is an available selection for Day and Month

Rheumatoid factor (RF) status

Indicate the Rheumatoid factor (RF) status by selecting from the drop-down list:

- Negative
- Positive
- Unknown

Rheumatoid factor (RF) titer (IU/mL)

Record the Rheumatoid factor (RF) titer at screening in IU/mL.

Note: This field is only enabled if "Rheumatoid factor (RF) status" is "Positive"

Date of Anti-Citrullinated Protein Antibody (ACPA) test:

Record the date of Anti-Citrullinated Protein Antibody (ACPA) test in the **DD/MMM/YYYY** format. A complete date is required.

Note: A year is required for start date. "**Unknown**" is an available selection for Day and Month

Anti-Citrullinated Protein Antibody (ACPA) status

Indicate the **Anti-Citrullinated Protein Antibody (ACPA) status** by selecting from the drop-down list:

- Negative
- Positive
- Unknown

Anti-Citrullinated Protein Antibody (ACPA) titer

Record the Anti-Citrullinated Protein Antibody (ACPA) titer.

Note: This field is only enabled if "Anti-Citrullinated Protein Antibody (ACPA) status" is "Positive"

# RHEUMATOID ARTHRITIS SEROLOGY TESTING (RA) (CONTINUED)

**ACPA Unit** 

Select the **unit** for ACPA from the drop-down list:


- Units/U
  - CU
- EU/mL
- Other

Note: This field is only enabled if "Anti-Citrullinated Protein Antibody (ACPA) status" is "Positive"

Note: If "Other" is selected, provide a response in the "ACPA Unit Other, Specify:" field

### PRIOR RHEUMATOID ARTHRITIS TREATMENT MEDICATION 1

Only populates for subjects enrolled in protocol version 6.0 and above



If a medication is stopped for a period of time and started up again, it should be as two separate instances of the medication and so on.

Please record all DMARD treatments (including conventional synthetic, biologic and targeted synthetic) used since RA diagnosis. Do not record any pain relief medications or corticosteroids on this form.

Please record one drug treatment per line. If a combo treatment, please record each drug in the combo separately.

**Treatment/Medication Name:** Enter one **treatment/medication** into the text box provided.

Note: If treatment/medication is a combination, record each drug separately

## PRIOR RHEUMATOID ARTHRITIS TREATMENT MEDICATION 1 (CONTINUED)

**Type of treatment:** Select the **type of treatment** from the drop-down list:

• csDMARD (Methotrexate, Hydroxychloroquine)

• bDMARD or biosimilar (Adalimumab, Golimumab, Infliximab,...)

tsDMARD (Baricitinib, Filgotinib, Tofacitinib, Upadacitinib)

Steroids

Investigational Agent

Other

Note: If "Other" is selected, provide a response in the "If Type of treatment is

Other, Specify:" field

Start date: Record the start date of the treatment/medication in the DD/MMM/YYYY format.

Note: A year is required for start date. "Unknown" is an available selection for Day

and Month

Ongoing? Select **No** or **Yes** to indicate if the treatment/medication is currently **ongoing**.

Note: If the treatment/medication changes/updates from ongoing to resolved

during the study, update this field accordingly

End date: Record the end date of the treatment/medication in the DD/MMM/YYYY format.

Note: This field is only enabled if "Ongoing?" is "No". A year is required for end

date. "Unknown" is an available selection for Day and Month

Reason for Discontinuing Select the reason for discontinuing from the drop-down list:

Completed course of therapy

Inadequate response

Toxicity


Other

Note: This field is only enabled if "Ongoing?" is "No"

Note: If "Other" is selected, provide a response in the "If Reason for Discontinuing

is other, specify:" field

### ALCOHOL AND DRUG USE



Please record any Alcohol, and/or Drugs usage on this form that occurred within 1 year prior to signing informed consent.

Any current or past alcohol use in the past year?

Select No or Yes to indicate any current or past alcohol use in the past year.

A 'unit' of alcohol is the amount contained in 1/2 pint (284 ml) of beer, a single glass (125 ml) of table wine, a single glass (50 ml) of fortified wine, for example sherry, or a single measure (25 ml) of spirits, it approximates to 10 ml or 8 g of absolute alcohol.

Number of units of alcohol consumed per week

Record the number of units of alcohol consumed per week.

Note: This field is only enabled if "Any current or past alcohol use in the past year?" is "Yes"

Any current or past drugs use in the past year?

Select No or Yes to indicate any current or past drugs of abuse use in the past year.

Select all applicable categories:


Select all applicable box(es) regarding current or past drugs of abuse use in the past year from the options provided:

- Cannabinoids
- Opioids
- Stimulants
- Club Drugs
- Dissociative Drugs
- Hallucinogens
- Prescription Medications
- Other

Note: This field is only enabled if "Any current or past drugs of abuse use in the past year?" is "Yes"

Note: If "Other" is selected, provide a response in the "Other, specify:" field

## **TOBACCO USE**



Please record any Tobacco usage on this log form. Each log should record 1 type of Tobacco use.

Is the subject a Current or Former user of tobacco?

Indicate if the subject is a **current or former user of tobacco** by selecting from the drop-down list:

- Current
- Former

Type of Tobacco

Indicate the **type of tobacco** by selecting from the drop-down list:

- Cigarettes
- e-Cigarettes
- Cigars
- Pipe
- Smokeless Tobacco
- Other

Note: If "Other" is selected, provide a response in the "Other type of Tobacco, Specify:" field

Amount used:

Record the amount of tobacco used

## **TOBACCO USE (CONTINUED)**

Unit: Select the unit of the tobacco used from the drop-down list:

Pack

Cigarette

• Cigar

Milliliter

Ounces

Pipe

• Cartridge

Pouch

Other

Note: If "Other" is selected, provide a response in the "Other, specify:" field

Frequency Select the frequency of the tobacco used from the drop-down list:

Per day

Per week

Per month

Per year

Occasionally

Start date of tobacco use: Record the start date of tobacco use in the DD/MMM/YYYY format. A complete date

is required.

Note: A year is required for start date. "Unknown" is an available selection for Day

and Month

End date of tobacco use: Record the end date of tobacco use in the DD/MMM/YYYY format. A complete date

is required.


Note: This field is only visible if "Is the subject a Current or Former user of

tobacco?" is "Former"

Note: A year is required for start date. "Unknown" is an available selection for Day

and Month

# **VITAL SIGNS**



For the sake of brevity, the screenshot for this form only shows vital signs at Screening visit. Other visits and timepoints are comparable to the Screening image.

## **VITAL SIGNS (CONTINUED)**

Were vital signs taken? Indicate if vital signs were taken by selecting **No** or **Yes**.

**Date performed:** Record the **date performed** in the **DD/MMM/YYYY** format. A complete date is

required.

Note: This field is enabled if vital signs were taken at all visits

Time performed: Record the time performed in the HH:MM 24-hour clock format.

Note: This field is enabled if vital signs were taken at **all** visits

**Height (cm):** Record the **height** of the subject in **centimeters** in the field provided.

Note: This field is only visible at Screening visit

Weight (kg): Record the weight of the subject in kilograms (kg) in the field provided.

Note: This field is only visible at the following visits:

Screening
 Early Termination

Pre-Treatment 2

W8D56

End of Study

Unscheduled

Body mass index (BMI,

kg/m<sup>2</sup>)

This field is read only and is calculated automatically. Note: This field is only visible

at Screening visit

Systolic blood pressure

(mmHg):

Record the **systolic blood pressure** in **mmHg** in the field provided.

Note: This field is enabled if vital signs were taken at **all** visits

**Diastolic blood pressure** 

(mmHg):

Record the **diastolic blood pressure** in **mmHg** in the field provided.

Note: This field is enabled if vital signs were taken at **all** visits

**Heart rate (bpm):** Record the **heart rate in beats per minute (bpm)** in the field provided.

Note: This field is enabled if vital signs were taken at all visits

**Temperature (C):** Record the **temperature** in **Celsius (C)** in the field provided.

Note: This field is enabled if vital signs were taken at **all** visits

Respiratory rate

(breaths/min):

Record the **respiratory rate** in **breaths/min** in the field provided. Note: *This field is enabled if vital signs were taken at all visits* 

In what position was the subject during the measurement?

Select the **position** the subject was during the measurement from the drop-down list:

- SITTING
- STANDING
- SUPINE
- SEMI-RECLINED

Note: This field is enabled if vital signs were taken at all visits

## **VITAL SIGNS (CONTINUED)**

The below are only visible at W1D1 visit and will be enabled for completion if "Yes" is selected for the following fields:

- Were vital signs 15 minutes post-infusion taken?
- Were vital signs 30 minutes post-infusion taken?
- Were vital signs 45 minutes post-infusion taken?
- Were vital signs 60 minutes post-infusion taken?
- Were vital signs 4 hours post-infusion taken?
- Were vital signs 8 hours post-infusion taken?
- Were vital signs 12 hours post-infusion taken?
- Were vital signs 16 hours post-infusion taken?
- Were vital signs 20 hours post-infusion taken?
- Were vital signs 24 hours post-infusion taken?

| Date performed: | Record the date performed in the DD/MMM/YYYY | format. A complete date is |
|-----------------|--|----------------------------|
|                 |  |                            |

required.

Note: At **W1D1**, this field is enabled if vital signs were taken at the following timepoints:

eponis.

Pre-infusion • 16 hours post-infusion

• 8 hours post-infusion

20 hours post-infusion

• 12 hours post-infusion

24 hours post-infusion

Time performed: Record the time performed in the HH:MM 24-hour clock format.

Systolic blood pressure

(mmHg):

Record the **systolic blood pressure** in **mmHg** in the field provided.

Diastolic blood pressure

(mmHg):

Record the diastolic blood pressure in mmHg in the field provided.

Heart rate (bpm): Record the heart rate in beats per min (bpm) in the field provided.

**Temperature (C):** Record the **temperature** in **Celsius (C)** in the field provided.

Respiratory rate

(breaths/min):


Record the **respiratory rate** in **breaths/min** in the field provided.

In what position was the subject during the measurement?

Select the position the subject was during the measurement from the drop-down list:

- SITTING
- STANDING
- SUPINE
- SEMI-RECLINED

### VITAL SIGNS - OXYGEN SATURATION



Were oxygen saturation readings taken?

Indicate if oxygen saturation readings were taken by selecting No or Yes.

Date performed:

Record the **date performed** in the **DD/MMM/YYYY** format. A complete date is

required.

Note: This field is enabled if vital signs were taken at **all** visits

Oxygen Saturation (%)

Record the **oxygen saturation** of the subject in **percentage** in the field provided. Note: *This field is only visible at* **Screening**, **Pre-Treatment 2**, **Pre-Treatment** 


Reassessment X Visit 2, W1D1, and Unscheduled visit

The below are only visible at W1D1 visit and will be enabled for completion if "Yes" is selected for the following fields:

- Were oxygen saturation readings 15 minutes post-infusion taken?
- Were oxygen saturation readings 30 minutes post-infusion taken?
- Were oxygen saturation readings 45 minutes post-infusion taken?
- Were oxygen saturation readings 60 minutes post-infusion taken?
- Were oxygen saturation readings 4 hours post-infusion taken?
- Were oxygen saturation readings 8 hours post-infusion taken?
- Were oxygen saturation readings 12 hours post-infusion taken?
   Were oxygen saturation readings 16 hours post-infusion taken?
- Were oxygen saturation readings 20 hours post-infusion taken?
- Were oxygen saturation readings 24 hours post-infusion taken?

X minutes/hours postinfusion Oxygen Saturation (%) Record the **oxygen saturation** of the subject in **percentage** in the field provided.

### PHYSICAL EXAMINATION 1



Record any abnormal and clinically significant findings on the Medical History or Adverse Events eCRF as appropriate. Indicate any clinically significant findings of the physical exam related to Medical History, Adverse Events, or Rheumatoid Arthritis on this form.

Was the physical examination performed?

Select **No** or **Yes** to indicate if the **physical examination** was performed.

Type of physical examination

Select **type of physical examination** from the drop down list:

- Complete
- Symptom Directed

Date performed:

Record the **date performed** in the **DD/MMM/YYYY** format. A complete date is required.

Were there any abnormal and clinically significant findings or changes since the last exam?

Select No or Yes to indicate if there were any abnormal and clinically significant findings or changes since the last exam.

## PHYSICAL EXAMINATION 1 (CONTINUED)

Indicate below which body systems had any abnormal and clinically significant findings since the last exam with a "Yes" response. If no findings or not assessed, then a "No" or "Not Done" response is expected. Then record the indication and brief description of each finding on a corresponding Physical Examination 1 - Clinical Findings log.

Select **Not Done** to indicate if the <u>physical exam was not done for that body system.</u>


**Select No to indicate** there were no clinically significant findings or clinically significant changes in the body systems from last exam for the following fields.

Select **Yes** to indicate <u>if there were any clinically significant findings or clinically significant</u> changes in the body systems from last exam for the following fields:

- Cardiovascular
- Respiratory
- Gastrointestinal
- Neurological
- Musculoskeletal
- Dermatological
- Other

Note: If Yes is selected for "Other", provide a response in the "Other Body system, specify:" field

### PHYSICAL EXAMINATION 1 – CLINICAL FINDINGS



#### **Indicate Body System**

Indicate body system from the drop down list:

- Cardiovascular
- Respiratory
- Gastrointestinal
- Neurological
- Dermatologic
- Musculoskeletal
- Other

Note: If **Yes** is selected for "**Other**", provide a response in the "**Other Body system**, **specify:**" field

#### **Primary Indication**

Select the primary indication from the drop down list:

- Adverse Event
- Medical History
- Rheumatoid Arthritis

<u>Note</u>: If "Adverse Event" or "Medical History" are selected, record the corresponding primary adverse event/medical history number in the "Primary Indication # in EDC" field


#### **Description of finding:**

Record **description of findings** in the text box provided.

<u>Note</u>: Only visible if "**Adverse Event**" or "**Medical History**" are selected for **Primary Indication** 

Note – Physical exam findings should only be noted for clinical finding during the actual physical exam, e.g. rash, etc. Any medical history during the screening visit should be recorded as such unless it is newly identified during the physical exam.

## 12-LEAD ELECTROCARDIOGRAM - TRIPLICATE



For the sake of brevity, the screenshot for this form only shows 12-Lead Electrocardiogram Reading 1. Reading 2 and Reading 3 fields are comparable to the Reading 1 image.

# 12-LEAD ELECTROCARDIOGRAM – TRIPLICATE (CONTINUED)

ECGs should be performed after the subject has been at rest for at least 5 minutes, and whilst in a supine or sitting position.

Was a 12-Lead ECG

performed?

Select No or Yes to indicate if the 12-Lead ECG was performed.

**Date performed:** Record the **date performed** in the **DD/MMM/YYYY** format. A complete date is

required.

Was the ECG performed with the subject in a supine or sitting position?

Select No or Yes to indicate if the ECG was performed with the subject in a

supine or sitting position.

If not supine or sitting, indicate position

Select the **position** the subject was during the measurement from the drop-down list:

- DECUBITUS
- FOWLERS
- LATERAL DECUBITUS
- LEFT LATERAL DECUBITUS
- PRONE
- REVERSE TRENDELENBURG
- RIGHT LATERAL DECUBITUS
- SEMI-FOWLERS
- SEMI-RECUMBENT
- SLING
- STANDING
- TRENDELENBURG
- UNCONSTRAINED

#### Reading 1

Time performed: Record the ECG time performed in the HH:MM 24-hour clock format.

**Heart rate (bpm):** Record the **heart rate** in **beats per minute (bpm)** in the field provided.

PR interval (msec): Record the PR interval in milliseconds (msec) in the field provided.

QRS duration (msec): Record the QRS interval in milliseconds (msec) in the field provided.

QT interval (msec): Record the QT interval in milliseconds (msec) in the field provided.

QTcF interval (msec): Record the QTcF interval in milliseconds (msec) in the field provided.

RR interval (msec): Record the RR interval in milliseconds (msec) in the field provided.

## 12-LEAD ELECTROCARDIOGRAM - TRIPLICATE (CONTINUED)

### Reading 2

Time performed: Record the ECG time performed in the HH:MM 24-hour clock format.

**Heart rate (bpm):** Record the **heart rate** in **beats per minute (bpm)** in the field provided.

PR interval (msec): Record the PR interval in milliseconds (msec) in the field provided.

QRS duration (msec): Record the QRS interval in milliseconds (msec) in the field provided.

QT interval (msec): Record the QT interval in milliseconds (msec) in the field provided.

QTcF interval (msec): Record the QTcF interval in milliseconds (msec) in the field provided.

RR interval (msec): Record the RR interval in milliseconds (msec) in the field provided.

Reading 3

Time performed: Record the ECG time performed in the HH:MM 24-hour clock format.

**Heart rate (bpm):** Record the **heart rate in beats per minute (bpm)** in the field provided.

PR interval (msec): Record the PR interval in milliseconds (msec) in the field provided.

QRS duration (msec): Record the QRS interval in milliseconds (msec) in the field provided.

QT interval (msec): Record the QT interval in milliseconds (msec) in the field provided.

QTcF interval (msec): Record the QTcF interval in milliseconds (msec) in the field provided.

RR interval (msec): Record the RR interval in milliseconds (msec) in the field provided.

QTcF Average (msec) This field is read only and is calculated automatically.

Overall interpretation: Select the overall interpretation of this 12-lead ECG from the drop-down list:

• ABNORMAL

NOT EVALUABLE

• INDETERMINATE

UNKNOWN


NORMAL

Was the overall interpretation clinically significant?

Select No or Yes to indicate if the overall interpretation was clinically significant.

### **CHEST X-RAY**

Chest X-Ray eCRF is only available for completion at Screening visit.



Was a standard posterioranterior and lateral chest xray obtained? Indicate if a **standard posterior-anterior and lateral chest x-ray** was obtained by selecting **No** or **Yes**.

Date of x-ray

Record the **date of X-Ray** in the **DD/MMM/YYYY** format. A complete date is required.

Were there any abnormal findings in the Chest X-Ray?

Indicate if there were **any abnormal findings in the Chest X-Ray** by selecting **No** or **Yes**.

Please specify any abnormal findings:

Record **any abnormal findings from X-Ray** in the text box provided.

Note: This field is only enabled if "Were there any abnormal findings in the Chest X-Ray?" is "Yes"


Were the abnormal findings clinically significant?

Indicate if the **abnormal findings were clinically significant** by selecting **No** or **Yes**.

Note: This field is only enabled if "Were there any abnormal findings in the Chest X-Ray?" is "Yes"

## SYNOVITIS ASSESSMENT

Synovitis Assessment eCRF is available for completion at **Screening**, **Pre-Treatment Visit 2**, and **Pre-Treatment Reassessment X Visit 2** (where **X = 1, 2, 3,...**) visits.



For the sake of brevity, the screenshot for this form does not show ALL of the joint fields visible on this form.

Was a Synovitis
Assessment performed using ultrasound?

Indicate if a **synovitis assessment** was performed by ultrasound by selecting **No** or **Yes**.

**Date of Assessment** 

If **Yes**, record the **date of assessment** in the **DD/MMM/YYYY** format. A complete date is required.

Left and Right Joints fields for the following sites will be enabled for completion if "Yes" is selected for "Was a Synovitis Assessment performed using ultrasound?":


Wrist 1st MCP (hand) Tibiotalar 2<sup>nd</sup> MTP (foot) 2<sup>nd</sup> MCP (hand) • 3<sup>rd</sup> MTP (foot) Elbow Talonavicular Shoulder • 3<sup>rd</sup> MCP (hand) 1<sup>st</sup> PIP (foot) 4th MTP (foot) 4th MCP (hand) 5<sup>th</sup> MTP (foot) 1st PIP (hand) 2<sup>nd</sup> PIP (foot) 2<sup>nd</sup> PIP (hand) 5<sup>th</sup> MCP (hand) 3<sup>rd</sup> PIP (foot) IP (foot) 3<sup>rd</sup> PIP (hand) IP (hand) 4<sup>th</sup> PIP (foot) Other • 4<sup>th</sup> PIP (hand) 1st MTP (foot) Knee

Indicate the scoring/grading for each site by selecting "0, 1, 2, or 3" from the drop down list.

Note: If "Other" is selected, provide a response in the "If L/R-Other, specify:" field

### SYNOVIAL BIOPSY AND FLUID COLLECTION

Synovial Biopsy and Fluid Collection eCRF is available for completion at **Screening**, **W4D28**, **W12D84**, **Early Termination**, and **Unscheduled** visits.



Was a Synovial Biopsy performed?

Indicate if a **synovial biopsy** was performed by selecting **No** or **Yes**.

Note: This field is NOT visible at W12D84 visit

Date of collection

Record the **date of collection** in the **DD/MMM/YYYY** format. A complete date is required.

Note: This field is NOT visible at **W12D84** visit

Biopsy from which joint?

Select the **location** of joint from the drop-down list:

Wrist, Left

Ankle, Left

Wrist, Right

Ankle, Right

• Knee, Left

Other

Knee, Right

Note: If "Other" is selected, provide a response in the "If Biopsy from which joint is

Other, specify:" field

Note: This field is NOT visible at W12D84 visit

# SYNOVIAL BIOPSY AND FLUID COLLECTION (CONTINUED)

Was Synovial Fluid

collected?

Indicate if a synovial fluid was collected by selecting No or Yes.

**Date of collection** Record the **date of collection** in the **DD/MMM/YYYY** format. A complete date is

required.

Fluid collection from which

joint?

Select the **location** of joint from the drop-down list:

Wrist, Left

• Ankle, Left

• Wrist, Right

Ankle, Right

Knee, Left

Other


• Knee, Right

 $\underline{\text{Note:}} \ \textit{If "Other"} \ \textit{is selected, provide a response in the "\textit{If Fluid collection from}$ 

which joint is Other, specify:" field

## APHERESIS ELIGIBILITY (PRE-TREATMENT)

Apheresis Eligibility eCRF is available for completion at **Screening, Pre-Treatment Visit 1**, and **Pre-Treatment Reassessment X Visit 1** (where **X = 1, 2, 3,...**) visits.



Did the subject meet all apheresis eligibility?

Select No or Yes to indicate if the subject met all apheresis eligibility.

Date of eligibility assessment:

Record the **date of eligibility assessment** in the **DD/MMM/YYYY** format. A complete date is required.

**Primary reason:** 

Select the **primary reason** from the drop-down list:

- CONCOMITANT MEDICATION
- CLINICALLY SIGNIFICANT MEDICAL EVENTS
- OTHER

Note: This field is only enabled if "Did the subject meet all apheresis eligibility?" is "No"

Primary reason if Concomitant Medication, Clinically Significant Medical Events, or Other, specify: Specify the **primary reason** in the text box provided.

Note: This field is only enabled if "Primary reason:" is "Concomitant Medication", "Clinically Significant Medical Events", or "Other"

# **APHERESIS ELIGIBITY (Pre-Treatment) (CONTINUED)**

Will the subject be eligible for reassessment at a later date?

Indicate if the **subject will be eligible for reassessment at a later date** by selecting from the drop-down list:

- No
- Yes
- Not applicable at this time

Note: This field is only enabled if "Did the subject meet all apheresis eligibility?" is "No"

Date of Screen Failure at Apheresis:

Record the date of Screen Failure at Apheresis phase in the DD/MMM/YYYY format. A complete date is required.

Note: This field is only enabled if "Will the subject be eligible for reassessment at a later date?" is "No"

Primary Reason for Screen Failure at Apheresis:

Select the **primary reason** from the drop-down list:


- ADVERSE EVENT
- FAILURE TO MEET APHERESIS ELIGIBILITY REQUIREMENTS
- STUDY TERMINATED BY SPONSOR
- WITHDRAWAL BY SUBJECT
- OTHER

Note: This field is only enabled if "Will the subject be eligible for reassessment at a later date?" is "No"

Note: If "Other" is selected, provide a response in the corresponding "Primary Reason for Screen Failure at Apheresis Other, Specify:" field

Page 62 of 157

#### **APHERESIS**



Apheresis eCRF is available for completion at **Pre-Treatment Visit 1**, and **Pre-Treatment Reassessment X Visit 1** (where **X = 1, 2, 3,...**) visits.

Did the subject undergo the apheresis procedure?

Select  ${f No}$  or  ${f Yes}$  to indicate if  ${f subject}$  underwent initial apheresis procedure.

Reason Apheresis Not Done:

Select the reason Apheresis not done from the drop down-list:

- ADVERSE EVENT
- OTHER

Note: If "Adverse Event" is selected, record the corresponding primary adverse event number in the "Specify Primary Adverse Event sequence number" field Note: If "Other" is selected, specify the primary cause of death in the "If Other, specify" field

## **APHERESIS (CONTINUED)**

Date of Apheresis Record the date of initial apheresis in the DD/MMM/YYYY format. A complete date

is required.

Note: This field is only enabled if "Did the subject undergo initial apheresis

procedure?" is "Yes"

Apheresis Start time (24hr

clock):

Record the Apheresis start time in the HH:MM 24-hour clock format.

Apheresis End time (24hr clock):

Record the Apheresis end time in the HH:MM 24-hour clock format.

Was Apheresis Successful?

Select No or Yes to indicate if initial apheresis was successful.

Note: This field is only enabled if "Did the subject undergo initial apheresis

procedure?" is "Yes"

Reason Apheresis Not Successful:

Select the **reason Apheresis not done** from the drop down-list:

ADVERSE EVENT

OTHER

Note: If "Adverse Event" is selected, record the corresponding primary adverse event number in the "Specify Primary Adverse Event sequence number" field Note: If "Other" is selected, specify the primary cause of death in the "If Other, provide" field

specify" field

Was Cell Manufacturing Successful?

Select **No** or **Yes** to indicate if **cell manufacturing was successful**.

Note: This field is only enabled if "Was Apheresis Successful?" is "Yes"

Reason Cell Manufacturing Not Successful:


Select the reason cell manufacturing was not successful from the drop down-list:

- ADVERSE EVENT
- OTHER

Note: If "Adverse Event" is selected, record the corresponding primary adverse event number in the "Specify Primary Adverse Event sequence number" field Note: If "Other" is selected, specify the reason cell manufacturing was not successful in the "Reason Cell Manufacturing Not Successful Other, specify" field

## LOCAL LABORATORY - SEROLOGICAL AND TUBERCULOSIS TESTS

Local Laboratory - Serological and Tuberculosis Tests eCRF is only available for completion at Screening visit.



Was a serological test performed?

Select No or Yes to indicate if a serological test was performed.

**Collection date:** 

Record the **collection date** in the **DD/MMM/YYYY** format. A complete date is required.

Note: This field is only enabled if "Was a serological test performed?" is "Yes"

**Hepatitis B surface antigen:** 

Select the result of **Hepatitis B surface antigen** from the drop-down list:

- Positive
- Negative
- Not Done

Note: This field is only enabled if "Was a serological test performed?" is "Yes"

**Hepatitis C antibody:** 

Select the result of **Hepatitis C antibody** from the drop-down list:

- Positive
- Negative
- Not Done

Note: This field is only enabled if "Was a serological test performed?" is "Yes"

# LOCAL LABORATORY - SEROLOGICAL AND TUBERCULOSIS (CONTINUED)

HBV DNA: Select the result of HBV DNA from the drop-down list:

PositiveNegativeNot Done

Note: This field is only enabled if "Hepatitis B surface antigen:" is "Positive"

HCV RNA: Select the result of HCV RNA from the drop-down list:

PositiveNegativeNot Done

Note: This field is only enabled if "Hepatitis C antibody:" is "Positive"

Was a tuberculosis assessment performed?

Select No or Yes to indicate if a tuberculosis assessment was performed.

Collection date: Record the collection date in the DD/MMM/YYYY format. A complete date is

required.

Note: This field is only enabled if "Was a tuberculosis assessment performed?" is

"Yes"

Quantiferon Gold results: Select the Quantiferon Gold results from the drop-down list:

Positive

Negative

Indeterminate


Note: This field is only enabled if "Was a tuberculosis assessment performed?" is

"Yes"

Page 66 of 157

### LOCAL LABORATORY - PREGNANCY

Serum pregnancy fields are available for completion at Screening, Pre-Treatment Visit 2, Pre-Treatment Reassessment X Visit 2 (where X = 1, 2, 3,...), W1D1, W12D84, W18D126, W24D168, Early Termination, End of Study, and Unscheduled visits. Urine pregnancy fields are only available for completion at W1D1, W12D84, W18D126, W24D168, Early Termination, End of Study, and Unscheduled visits.



For the sake of brevity, the screenshot for this form only shows pregnancy lab at W1D1 visit. Other visits are comparable to the W1D1 image.

Was the urine pregnancy test collected?

Select No or Yes to indicate if a urine pregnancy test was collected.

Note: This field is only visible at W1D1, W12D84, W18D126, W24D168, Early

Termination, End of Study, and Unscheduled visits

Urine pregnancy collection date:

Record the **urine pregnancy collection date** in the **DD/MMM/YYYY** format. A complete date is required.

Note: This field is only enabled if "Was the urine pregnancy test collected?" is "Yes"

Note: This field is only visible at W1D1, W12D84, W18D126, W24D168, Early Termination, End of Study, and Unscheduled visits

Urine pregnancy collection time (24hr clock)

Record the **urine pregnancy collection time** performed in the **HH:MM 24-hour clock** format.

Note: This field is only enabled if "Was the urine pregnancy test collected?" is "Yes"

Note: This field is only visible at W1D1 visit

# **LOCAL LABORATORY – PREGNANCY (CONTINUED)**

Urine pregnancy result: Select the urine pregnancy result from the drop-down list:

Positive

• Negative
Note: This field is only enabled if "Was the urine pregnancy test collected?" is

"Yes"

Note: This field is only visible at W1D1, W12D84, W18D126, W24D168, Early

Termination, End of Study, and Unscheduled visits

Was the serum pregnancy test collected?

Select **No** or **Yes** to indicate if a **serum pregnancy test** was collected.

Serum pregnancy collection date:

Record the serum pregnancy collection date in the DD/MMM/YYYY format. A

complete date is required.

Note: This field is only enabled if "Was the serum pregnancy test collected?" is

"Yes"

Serum pregnancy collection time (24hr clock)

Record the serum pregnancy collection time performed in the HH:MM 24-hour

clock format.

Note: This field is only enabled if "Was the serum pregnancy test collected?" is

"Yes"

Note: This field is only visible at W1D1 visit

**Serum pregnancy result:** 


Select the **serum pregnancy result** from the drop-down list:

- Positive
- Negative

Note: This field is only enabled if "Was the serum pregnancy test collected?" is "Yes"

## LOCAL LABORATORY - POST MENOPAUSE

Local Laboratory - Post Menopause eCRF is only available for completion at Screening visit.



Was a post-menopausal assessment was performed?

Collection date:

Record the collection date in the DD/MMM/YYYY format. A complete date is required.

Follicle-Stimulating Record the Follicle-Stimulating Hormone (FSH, IU/L)

Record the Follicle-Stimulating Hormone (FSH) (round to the nearest tenth) in IU/L in the field provided.

Estradiol (pg/ml)

Record the Estradiol in pg/ml in the field provided.

## LOCAL LABORATORY - COAGULATION

Local Laboratory – Coagulation eCRF is available for completion at **Screening**, **Pre-Treatment Visit 2**, **Pre-Treatment Reassessment X Visit 2** (where X = 1, 2, 3,...), W18D126, W24D168, and End of Study visits.



## LOCAL LABORATORY - COAGULATION (CONTINUED)

Was coagulation sample

collected?

Select No or Yes to indicate if a coagulation sample was collected.

Collection date: Record the collection date in the DD/MMM/YYYY format. A complete date is

required.

Was a primary local laboratory used?

Select **No** or **Yes** to indicate if a **a primary local laboratory** was used.

Note: If "No" is selected, enter the range in the lower and upper limit fields for the

indicated parameters

**Lab name:** Select the corresponding **lab name** from the drop-down list.

Note: If a lab name is selected, the lower and upper limit fields are not required for

data entry

Note: If the required lab name is unavailable, please contact your CRA and Medpace

Data Management

**Results:** Record the **test results** for the following parameters. If the parameter was not

collected, select the 'Not Done' checkbox.

Prothrombin time (PT, seconds)

• International normalized ratio (INR)

Activated partial thromboplastin time (aPTT, seconds)

Out of Range? Select No or Yes to indicate if the test result was out of range.

Clinically Significant? Select No or Yes to indicate if the out of range test result was clinically significant.


Note: This field is only enabled if "Out of Range?" is "Yes"

Note: If this field is "Yes", please record any clinically significant findings on the

Medical History or Adverse Events eCRF as appropriate.

Page 71 of 157

## LOCAL LABORATORY - HEMATOLOGY 1



For the sake of brevity, not all the available analytes are shown in the above image.

### LOCAL LABORATORY - HEMATOLOGY 1 (CONTINUED)

Any clinically significant findings that occur after first dose of study drug should be reported on the Adverse Event Form.

Was hematology sample

collected?

Select **No** or **Yes** to indicate if the **hematology sample** was collected.

Collection date: Record the collection date in the DD/MMM/YYYY format. A complete date is

required.

Collection time (24-hour

clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

Was a primary local laboratory used?

Select **No** or **Yes** to indicate if a **primary local laboratory** was used.

Note: If "No" is selected, enter the range in the lower and upper limit fields for the

indicated parameters

**Lab name:** Select the corresponding **lab name** from the drop-down list.

Note: If a lab name is selected, the lower and upper limit fields are not required for

data entry

Note: If the required lab name is unavailable, please contact your CRA and Medpace

Data Management

Complete the following fields for each parameter listed if available.

**Results:** Record the **test results** for the following parameters. If the parameter was not

collected, select the 'Not Done' checkbox.

Hematocrit (Hct)

- Hemoglobin (Hb)
- Platelet count
- Red blood count (RBC)
- % Reticulocytes
- Mean corpuscular volume (MCV)
- Mean corpuscular hemoglobin (MCH)

## LOCAL LABORATORY - HEMATOLOGY 1 (CONTINUED)

Unit:

Select the corresponding **unit** for the parameter from the drop down-list (if applicable):

- %
- fL
- g/dL
- mcm<sup>3</sup>
- pg
- x 10<sup>3</sup>/mcL
- x 10^6/mcL
- x 10^9/L
- x 10<sup>1</sup>2/L
- K/mm<sup>3</sup>
- M/mcL
- Other

Note: If "Other" is selected, provide a response in the corresponding "Unit Other, specify:" field

Out of Range?

Select **No** or **Yes** to indicate if the test result was **out of range**.

**Clinically Significant?** 


Select No or Yes to indicate if the out-of-range test result was clinically significant.

Note: This field is only enabled if "Out of Range?" is "Yes"

Note: If this field is "Yes", please record any clinically significant findings on the

Medical History or Adverse Events eCRF as appropriate.

### LOCAL LABORATORY - HEMATOLOGY 2



For the sake of brevity, not all the available analytes are shown in the above image.

### LOCAL LABORATORY - HEMATOLOGY 2 (CONTINUED)

Any clinically significant findings that occur after first dose of study drug should be reported on the Adverse Event Form.

Was hematology sample

collected?

Select **No** or **Yes** to indicate if the **hematology sample** was collected.

Collection date: Record the collection date in the DD/MMM/YYYY format. A complete date is

required.

Collection time (24-hour

clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

Was a primary local laboratory used?

Select **No** or **Yes** to indicate if a **primary local laboratory** was used.

Note: If "No" is selected, enter the range in the lower and upper limit fields for the

indicated parameters

**Lab name:** Select the corresponding **lab name** from the drop-down list.

Note: If a lab name is selected, the lower and upper limit fields are not required for

data entry

Note: If the required lab name is unavailable, please contact your CRA and Medpace

Data Management

Complete the following fields for each parameter listed if available.

**Results:** Record the **test results** for the following parameters. If the parameter was not collected, select the **'Not Done'** checkbox.

• White blood count (WBC)

- Absolute Neutrophil count
- Absolute Lymphocyte count
- Absolute Monocyte count
- Absolute Eosinophil count
- Absolute Basophil count
- Neutrophils (Differential, %)
- Lymphocytes (Differential, %)
- Monocytes (Differential, %)
- Eosinophils (Differential, %)
- Basophils (Differential, %)

## LOCAL LABORATORY - HEMATOLOGY 2 (CONTINUED)

**Unit:** Select the corresponding **unit** for the parameter from the drop down-list (if applicable):

x 10<sup>3</sup>/mcLx 10<sup>9</sup>/LK/mm<sup>3</sup>

Other

Note: If "Other" is selected, provide a response in the corresponding "Unit Other, specify:" field

Out of Range? Select No or Yes to indicate if the test result was out of range.

Clinically Significant? Select No or Yes to indicate if the out of range test result was clinically significant.


Note: This field is only enabled if "Out of Range?" is "Yes"

 $\underline{\text{Note:}} \ \textit{If this field is "Yes"}, \ \textit{please record any clinically significant findings on the}$ 

Medical History or Adverse Events eCRF as appropriate.

Page 77 of 157

## LOCAL LABORATORY - HIV SCREENING



Was HIV testing completed? Select No or Yes to indicate if HIV testing was completed

Collection date: Record the collection date in the DD/MMM/YYYY format. A complete date is

required.

HIV testing results: Select Positive or Negative to indicate if HIV testing results

### LOCAL LABORATORY - CLINICAL CHEMISTRY 1



For the sake of brevity, not all the available analytes are shown in the above image.

### LOCAL LABORATORY - CLINICAL CHEMISTRY 1 (CONTINUED)

Any clinically significant findings that occur after first dose of study drug should be reported on the Adverse Event Form.

Was clinical chemistry sample collected?

Select No or Yes to indicate if the chemistry sample was collected.

Collection date: Record the collection date in the DD/MMM/YYYY format. A complete date is

required.

Collection time (24-hour

clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

Was a primary local laboratory used?

Select No or Yes to indicate if a primary local laboratory was used.

Note: If "No" is selected, enter the range in the lower and upper limit fields for the

indicated parameters

**Lab name:** Select the corresponding **lab name** from the drop-down list.

Note: If a lab name is selected, the lower and upper limit fields are not required for

data entry

Note: If the required lab name is unavailable, please contact your CRA and Medpace

Data Management

Complete the following fields for each parameter listed if available.

**Results:** Record the **test results** for the following parameters. If the parameter was not

collected, select the 'Not Done' checkbox.

- Alanine aminotransferase (ALT)
- Albumin
- Alkaline phosphatase
- Aspartate aminotransferase (AST)
- Bicarbonate
- Blood urea nitrogen (BUN)
- Calcium
- Chloride
- Creatinine

## LOCAL LABORATORY - CLINICAL CHEMISTRY 1 (CONTINUED)

**Unit:** Select the corresponding **unit** for the parameter from the drop down-list (if applicable):

- g/dL
- mEq/L
- mg/dL
- mmol/L
- U/L
- Other

Note: If "Other" is selected, provide a response in the corresponding "Unit Other, specify:" field

Out of Range? Select No or Yes to indicate if the test result was out of range.

**Clinically Significant?** Select **No** or **Yes** to indicate if the out of range test result was **clinically significant**.


Note: This field is only enabled if "Out of Range?" is "Yes"

Note: If this field is "Yes", please record any clinically significant findings on the

Medical History or Adverse Events eCRF as appropriate.

Page 81 of 157

### LOCAL LABORATORY - CLINICAL CHEMISTRY 2



For the sake of brevity, not all the available analytes are shown in the above image.

### LOCAL LABORATORY - CLINICAL CHEMISTRY 2 (CONTINUED)

Any clinically significant findings that occur after first dose of study drug should be reported on the Adverse Event Form.

Was clinical chemistry sample collected?

Select No or Yes to indicate if the chemistry sample was collected.

Collection date: Record the collection date in the DD/MMM/YYYY format. A complete date is

required.

Collection time (24-hour

clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

Was a primary local laboratory used?

Select No or Yes to indicate if a primary local laboratory was used.

Note: If "No" is selected, enter the range in the lower and upper limit fields for the

indicated parameters

**Lab name:** Select the corresponding **lab name** from the drop-down list.

Note: If a lab name is selected, the lower and upper limit fields are not required for

data entry

Note: If the required lab name is unavailable, please contact your CRA and Medpace

Data Management

Complete the following fields for each parameter listed if available.

**Results:** Record the **test results** for the following parameters. If the parameter was not

collected, select the 'Not Done' checkbox.

Non-Fasting Glucose

- Fasting Glucose
- Direct bilirubin
- Total bilirubin
- Total protein
- Potassium
- Sodium
- HbA1c

## LOCAL LABORATORY - CLINICAL CHEMISTRY 2 (CONTINUED)

**Unit:** Select the corresponding **unit** for the parameter from the drop down-list (if applicable):

- %
- g/dL
- g/L
- mg/dL
- mEq/L
- mmol/L
- Other

Note: If "Other" is selected, provide a response in the corresponding "Unit Other, specify:" field

Out of Range? Select No or Yes to indicate if the test result was out of range.

**Clinically Significant?** Select **No** or **Yes** to indicate if the out of range test result was **clinically significant**.


Note: This field is only enabled if "Out of Range?" is "Yes"

Note: If this field is "Yes", please record any clinically significant findings on the

Medical History or Adverse Events eCRF as appropriate.

### LOCAL LABORATORY - CREATININE CLEARANCE/EGFR

Local Laboratory - Creatinine Clearance/eGFR eCRF is only available for completion at Screening visit.



Any clinically significant findings that occur after first dose of study drug should be reported on the Adverse Event Form.

Was eGRF assessed using the CKD-EPI method?

Collection date

Record the collection date in the DD/MMM/YYYY format. A complete date is required.

Select the eGFR result sign from the drop-down list:

Collection date

Select the eGFR result sign from the drop-down list:

Collection date in the DD/MMM/YYYY format. A complete date is required.

eGFR result Record the eGFR result in the field provided.

## LOCAL LABORATORY - URINALYSIS



For the sake of brevity, not all the available analytes are shown in the above image.

### LOCAL LABORATORY - URINALYSIS (CONTINUED)

Any clinically significant findings that occur after first dose of study drug should be reported on the Adverse Event Form.

Was a urine sample

collected?

Select **No** or **Yes** to indicate if the **urine sample** was collected.

Collection date: Record the collection date in the DD/MMM/YYYY format. A complete date is

required.

Any abnormal results? Select No or Yes to indicate if there are any abnormal results.

Were any abnormal results clinically significant?

Select No or Yes to indicate if there are any abnormal clinically significant results.

Note: This field is only visible if "Any abnormal results?" is "Yes"

Note: If this field is "Yes", please record any clinically significant findings on the

Medical History or Adverse Events eCRF as appropriate.

Select all that apply to indicate which tests were performed and had abnormal clinically significant results:

Select all applicable box(es) regarding abnormal clinically significant results from the drop-down list:

**Bacteria** 

Bilirubin

Casts

Color

Clarity

**Crystals** 

**Epithelial Cells** 

**Erythrocytes (RBC)** 

**Fat Droplet** 

Glucose

**Ketones** 

**Ketone Bodies** 

**Hyaline Casts** Leukocyte Esterase

Leukocytes (WBC)

**Nitrite** 

**Occult Blood** 

**Protein** 

Sediment Examination / **Microscopic Sediment** 

**Analysis** 

**Specimen Appearance** 

Spermatozoa

**Trichomonas** 

Urobilinogen

**Yeast Cells** 

На


Protein/Creatinine

**Specific Gravity** 

Other

Note: If "Other" is selected, provide a response in the "Other, specify" field Note: This field is only visible if "Were any abnormal results clinically significant?" is "Yes"

### LOCAL LABORATORY - LIPID TESTS



## LOCAL LABORATORY - LIPID TESTS (CONTINUED)

Any clinically significant findings that occur after first dose of study drug should be reported on the Adverse Event Form.

Was Lipid Test sample

collected?

Select No or Yes to indicate if the lipid test sample was collected.

Collection date: Record the collection date in the DD/MMM/YYYY format. A complete date is

required.

Collection time (24-hour

clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

Was a primary local laboratory used?

Select **No** or **Yes** to indicate if a **primary local laboratory** was used.

Note: If "No" is selected, enter the range in the lower and upper limit fields for the

indicated parameters

**Lab name:** Select the corresponding **lab name** from the drop-down list.

Note: If a lab name is selected, the lower and upper limit fields are not required for

data entry

Note: If the required lab name is unavailable, please contact your CRA and Medpace

Data Management

Complete the following fields for each parameter listed if available.

**Results:** Record the **test results** for the following parameters. If the parameter was not

collected, select the 'Not Done' checkbox.

Total cholesterol

LDL

Page 89 of 157

## LOCAL LABORATORY - LIPID TESTS (CONTINUED)

**Unit:** Select the corresponding **unit** for the parameter from the drop down-list (if applicable):

• mg/dL

• Other

Note: If "Other" is selected, provide a response in the corresponding "Unit Other,

specify:" field

Out of Range? Select No or Yes to indicate if the test result was out of range.


Clinically Significant? Select No or Yes to indicate if the out of range test result was clinically significant.

Note: This field is only enabled if "Out of Range?" is "Yes"

Note: If this field is "Yes", please record any clinically significant findings on the

Medical History or Adverse Events eCRF as appropriate.

### C-REACTIVE PROTEIN/ERYTHROCYTE SEDIMENTATION RATE



Was a C-Reactive Protein (CRP) assessment performed?

Select **No** or **Yes** to indicate if the **C-Reactive Protein (CRP) assessment** was performed.

**Date of CRP assessment** 

Record the date of CRP assessment in the DD/MMM/YYYY format. A complete

date is required.

Note: This field is only enabled if "Was a C-Reactive Protein (CRP) assessment

performed?" is "Yes"

C-Reactive Protein (CRP, mg/L)

Record the C-Reactive Protein (CRP) in mg/L (round to the nearest tenth) in the

field provided.

Note: This field is only enabled if "Was a C-Reactive Protein (CRP) assessment

performed?" is "Yes"

Was an Erythrocyte Sedimentation Rate (ESR) assessment performed? Select **No** or **Yes** to indicate if the **Erythrocyte Sedimentation Rate (ESR)** assessment was performed.

**Date of ESR assessment** 

Record the date of ESR assessment in the DD/MMM/YYYY format. A complete

date is required.

Note: This field is only enabled if "Was an Erythrocyte Sedimentation Rate (ESR)

assessment performed?" is "Yes"


Erythrocyte Sedimentation Rate (ESR, mm/hr)

Record the Erythrocyte Sedimentation Rate (ESR) in mm/hr in the field provided. Note: This field is only enabled if "Was an Erythrocyte Sedimentation Rate (ESR)

assessment performed?" is "Yes"

## **JOINT COUNT ASSESSMENTS**

The information regarding Joint Count Assessments can be found on the Homunculus worksheet provided to the site.




| Was a Joint Count Assessment performed?          | Select <b>No</b> or <b>Yes</b> to indicate if the <b>joint count assessment</b> was performed.      |
|--|---|
| Date of assessment                               | Record the <b>date of assessment</b> in the <b>DD/MMM/YYYY</b> format. A complete date is required. |
| Total Number Swollen Joints (DAS28)              | Record the <b>Total Number Swollen Joints (DAS28)</b> in the field provided.                        |
| Total Number Swollen Joints (DAS28) Not Assessed | Record the <b>Total Number Swollen Joints (DAS28) was not assessed</b> in the field provided.       |
| Total Number Tender Joints (DAS28)               | Record the <b>Total Number Tender Joints (DAS28)</b> in the field provided.                         |
| Total Number Tender Joints (DAS28) Not Assessed  | Record the <b>Total Number Tender Joints (DAS28) was not assessed</b> in the field provided.        |

## **JOINT COUNT ASSESSMENTS (CONTINUED)**

| Total Number Swollen Joints (66)              | Record the <b>Total Number Swollen Joints (66)</b> in the field provided.                  |
|---|--|
| Total Number Swollen Joints (66) Not Assessed | Record the <b>Total Number Swollen Joints (66) was not assessed</b> in the field provided. |
| Total Number Tender Joints (68)               | Record the <b>Total Number Tender Joints (68)</b> in the field provided.                   |
| Total Number Tender Joints (68) Not Assessed  | Record the <b>Total Number Tender Joints (68) was not assessed</b> in the field provided.  |

## **VISUAL ANALOG SCALE (VAS)**



### Measured from left to right in mm

Was the Subject's Global Assessment of Arthritis completed at this visit?

Select **No** or **Yes** to indicate if the **Subject's Global Assessment of Arthritis** was completed.

Date of Subject's Global assessment:

Record the **date of Subject's Global assessment** in the **DD/MMM/YYYY** format. A complete date is required.

Note: This field is only enabled if "Was the Subject's Global Assessment of Arthritis completed at this visit?" is "Yes"

Subject's Global Assessment (mm)

Record the **Subject's Global Assessment** in **millimeter (mm)** in the field provided.

<u>Note:</u> This field is only enabled if "Was the Subject's Global Assessment of

Arthritis completed at this visit?" is "Yes"

## **VISUAL ANALOG SCALE (VAS) (CONTINUED)**

Was the Subject's Assessment of Arthritis Pain completed at this visit? Select No or Yes to indicate if the Subject's Assessment of Arthritis Pain was

completed.

**Date of Subject's Pain** 

assessment:

Record the date of Subject's Pain assessment in the DD/MMM/YYYY format. A

complete date is required.

Note: This field is only enabled if "Was the Subject's Assessment of Arthritis Pain

completed at this visit?" is "Yes"

**Subject's Pain Assessment** 

(mm)

Record the **Subject's Pain Assessment** in **millimeter (mm)** in the field provided.

Note: This field is only enabled if "Was the Subject's Assessment of Arthritis Pain

completed at this visit?" is "Yes"

Was Physician's Global Assessment of Arthritis completed at this visit?

Select No or Yes to indicate if the Physician's Global Assessment of Arthritis was

completed.

Date of Physician's

Assessment:

Record the date of Physician's Assessment in the DD/MMM/YYYY format. A

complete date is required.

Note: This field is only enabled if "Was Physician's Global Assessment of

Arthritis completed at this visit?" is "Yes"

Physician's Global Assessment (mm)


Record the Physician's Global Assessment in millimeter (mm) in the field

provided.

Note: This field is only enabled if "Was Physician's Global Assessment of

Arthritis completed at this visit?" is "Yes"

## IMMUNE EFFECTOR CELL-ASSOCIATED ENCEPHALOPATHY (ICE) SCORE



Was an ICE score collected? Select No or Yes to indicate if the ICE score was collected. Date of ICE score collection Record the date of ICE score collection in the DD/MMM/YYYY format. A complete date is required. Time of ICE score collection Record the time of ICE score collection performed in the HH:MM 24-hour clock (24 hour clock): format. Select No or Yes to indicate if this ICE score collection was associated with a Was this ICE score collection associated with a neurotoxicity event. neurotoxicity event? Adverse Event # associated Record the Adverse Event # associated with this ICE score in the field provided.

with this ICE score

# IMMUNE EFFECTOR CELL-ASSOCIATED ENCEPHALOPATHY (ICE) SCORE (CONTINUED)

### Subject ICE Score

| Orientation        | Select the score for <b>orientation</b> from the  | drop-down list:   |  |
|--------------------|---|---|--|
|                    | • 0   | • 3   |  |
|                    | • 1   | • 4   |  |
|                    | • 2   | ·   |  |
|                    | Note: This field is visible at <b>all</b> visits including <b>Unscheduled</b> visits <b>except W1D1</b> visit |   |  |
| Naming             | Select the score for <b>naming</b> from the drop-down list:   |   |  |
|                    | • 0   | • 2   |  |
|                    | • 1   | • 3   |  |
|                    | Note: This field is visible at all visits including Unscheduled visits except W1D1 visit                      |   |  |
| Following Commands | Select the score for <b>following commands</b> from the drop-down list:                                       |   |  |
|                    | • 0   |   |  |
|                    | • 1   |   |  |
|                    | Note: This field is visible at all visits include   | ding Unscheduled visits except W1D1 visit               |  |
| Writing            | Select the score for <b>writing</b> from the drop-down list:  |   |  |
| · ·                | • 0   |   |  |
|                    | • 1   |   |  |
|                    | Note: This field is visible at all visits include   | ding Unscheduled visits except W1D1 visit               |  |
|                    |   |   |  |
| Attention          | ion Select the score for attention from the drop-down list:   |   |  |
|                    | • 0   |   |  |
|                    | • 1   |   |  |
|                    | Note: This field is visible at <b>all</b> visits include  | ding Unscheduled visits except W1D1 visit               |  |
| ICE Score          | This field is read only and is calculated au  | tomatically   |  |
| IOL GOOLE          | This held is read only and is calculated at   | iomatically.  |  |
|                    | Note: This field is visible at <b>all</b> visits include  | ding <b>Unscheduled</b> visits <b>except W1D1</b> visit |  |
|                    |   |   |  |

# IMMUNE EFFECTOR CELL-ASSOCIATED ENCEPHALOPATHY (ICE) SCORE (CONTINUED)

The below are only visible at **W1D1** visit and will be enabled for completion if "**Timepoint not done**" field is NOT selected for the following timepoints:

- Pre-dose
- 4 hours post-infusion
- 8 hours post-infusion
- 12 hours post-infusion
- 16 hours post-infusion
- 20 hours post-infusion
- 24 hours post-infusion

Date of ICE score collection

Record the date of ICE score collection in the DD/MMM/YYYY format. A complete

date is required.

Note: This field is only visible at the following timepoints: **8 hours post-infusion**, **12 hours post-infusion**, **16 hours post-infusion**, **20 hours post-infusion**, **24 hours** 

post-infusion

Time of ICE score collection (24 hour clock):

Record the time of ICE score collection performed in the HH:MM 24-hour clock

format

Note: This field is visible at all timepoints except Pre-dose timepoint

Orientation

Select the score for **orientation** from the drop-down list:

• 0

• 3

• 1

•

• 2

Naming Select the score for naming from the drop-down list:

• 2

• 1

• 3

**Following Commands** 

Select the score for following commands from the drop-down list:

• 0

• 1

Writing

Select the score for **writing** from the drop-down list:

• 0

• 1

**Attention** 

Select the score for attention from the drop-down list:


• 0

• 1


**ICE Score** 


This field is read only and is calculated automatically.

### HEALTH ASSESSMENT QUESTIONNAIRE - DISABILITY INDEX



The first portion of the Health Assessment Questionnaire – Disability Index eCRF is shown here. See subsequent parts on the following page(s).





Was the Health Assessment Questionnaire - Disability Index completed? Select **No** or **Yes** to indicate if the **Health Assessment Questionnaire - Disability Index** was completed.

Date completed:

Record the **date completed** in the **DD/MMM/YYYY** format. A complete date is required.

### **Dressing and Grooming**

Are you able to dress yourself, including shoelaces and buttons?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

Are you able to shampoo your hair?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

### **Arising**

Are you able to stand up from a straight chair?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

Are you able to get in and out of bed?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

### Eating

Are you able to cut your own meat?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

Are you able to lift a full cup or glass to your mouth?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

Are you able to open a new milk carton?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

### Walking

Are you able to walk outdoors on flat ground? Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

Are you able to climb up five steps?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

### AIDS or DEVICES - DAEW

Please check any AIDS or **DEVICES** that you usually use for any of the above activities

Select all applicable box(es) regarding AIDS or DEVICES that are usually used for any of the above activities from the drop-down list:

- Devices used for dressing
- Special or built up chair
- Built up or special utensils
- **Walking Frame**
- **Crutches**
- Wheelchair
- None

### HELP FROM ANOTHER PERSON - DAEW

Please check any categories for which you usually need **HELP FROM ANOTHER** PERSON:

Select all applicable box(es) regarding help from another person from the dropdown list:

- **Dressing and grooming**
- **Arising**
- **Eating**
- Walking
- None

### Hygiene

Are you able to wash and dry your body?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

Are you able to take a tub bath?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

Are you able to get on and off the toilet?

Select the **score** from the drop-down list:

- Without Any Difficulty 0
- With Some Difficulty 1
- With Much Difficulty 2
- Unable to Do 3

### Reach

| Are you able to reach and get down a 5 pound object (such as a bag of sugar) from above your head? | <ul> <li>Select the score from the drop-down list:</li> <li>Without Any Difficulty – 0</li> <li>With Some Difficulty – 1</li> </ul> | <ul> <li>With Much Difficulty – 2</li> <li>Unable to Do – 3</li> </ul> |
|--|---|--|
| Are you able to bend down to pick up clothing from the floor?                                      | <ul> <li>Select the score from the drop-down list:</li> <li>Without Any Difficulty – 0</li> <li>With Some Difficulty – 1</li> </ul> | <ul> <li>With Much Difficulty – 2</li> <li>Unable to Do – 3</li> </ul> |
|  | Grip  |  |
| Are you able to open car doors?  | <ul> <li>Select the score from the drop-down list:</li> <li>Without Any Difficulty – 0</li> <li>With Some Difficulty – 1</li> </ul> | <ul> <li>With Much Difficulty – 2</li> <li>Unable to Do – 3</li> </ul> |
| Are you able to open previously opened jars?   | <ul> <li>Select the score from the drop-down list:</li> <li>Without Any Difficulty – 0</li> <li>With Some Difficulty – 1</li> </ul> | <ul> <li>With Much Difficulty – 2</li> <li>Unable to Do – 3</li> </ul> |
| Are you able to turn faucets on and off?   | <ul> <li>Select the score from the drop-down list:</li> <li>Without Any Difficulty – 0</li> <li>With Some Difficulty – 1</li> </ul> | <ul> <li>With Much Difficulty – 2</li> <li>Unable to Do – 3</li> </ul> |
|  | Activities  |  |
| Are you able to run errands and shop?  | Select the <b>score</b> from the drop-down list:  • Without Any Difficulty – 0  • With Some Difficulty – 1                          | <ul> <li>With Much Difficulty – 2</li> <li>Unable to Do – 3</li> </ul> |
| Are you able to get in and out of a car?   | <ul> <li>Select the score from the drop-down list:</li> <li>Without Any Difficulty – 0</li> <li>With Some Difficulty – 1</li> </ul> | <ul> <li>With Much Difficulty – 2</li> <li>Unable to Do – 3</li> </ul> |
| Are you able to do chores such as vacuuming or yard work?  | Select the <b>score</b> from the drop-down list:  • Without Any Difficulty – 0  • With Some Difficulty – 1                          | <ul> <li>With Much Difficulty – 2</li> <li>Unable to Do – 3</li> </ul> |

#### AIDS or DEVICES - HRGA

Please check any AIDS or DEVICES that you usually use for any of the above activities Select all applicable box(es) regarding AIDS or DEVICES that are usually used for any of the above activities from the drop-down list:

- · Raised toilet seat
- Bathtub seat
- Bathtub bar
- Long-handled appliances in bathroom
- Jar opener
- None

### HELP FROM ANOTHER PERSON - HRGA

Please check any categories for which you usually need HELP FROM ANOTHER PERSON:

Select all applicable box(es) regarding **help from another person** from the drop-down list:

- Hygiene
- Reach
- · Gripping and opening things
- Activities
- None

#### PAIN

How much pain have you had IN THE PAST WEEK?
On a scale of 0 to 100 (where zero represents "no pain" and 100 represents "severe pain")

Record the numeric score regarding how much pain the subject had in the past week.

#### **HEALTH**

Please rate how well you are doing on a scale of 0 to 100 (where zero represents "very well" and 100 represents "very poor" health) Record the numeric score regarding how well the subject is doing.

# Please confirm if AIDS, DEVICES, and/or HELP FROM ANOTHER PERSON are used for all subcategories below:

**Dressing and Grooming** Select the **option** from the drop-down list:

None
 Help from another person only

• Aids or Devices only • Both

Arising Select the option from the drop-down list:

None
 Help from another person only

Aids or Devices only
 Both

**Eating** Select the **option** from the drop-down list:

None
 Help from another person only

• Aids or Devices only • Both

Walking Select the option from the drop-down list:

None
 Help from another person only

Aids or Devices only • Bot

**Hygiene** Select the **option** from the drop-down list:

None
 Help from another person only

• Aids or Devices only • Both

**Reach** Select the **option** from the drop-down list:

None
 Help from another person only

Aids or Devices only
 Both

**Grip** Select the **option** from the drop-down list:

None
 Help from another person only

Aids or Devices only
 Both

Activities Select the option from the drop-down list:

None
 Help from another person only


• Aids or Devices only • Both


### FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY - FATIGUE



The first portion of the Functional Assessment of Chronic Illness Therapy – Fatigue eCRF is shown here. See subsequent parts on the following page(s).

# FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY – FATIGUE (CONTINUED)





Please enter the Item Score (not Item Response) on this form.

| Was a FACIT-F assessment performed?           | Select <b>No</b> or <b>Yes</b> to indicate if the <b>FACIT-F assessment</b> was performed.          |                          |          |          |
|---|---|--------------------------|----------|----------|
| Date of assessment                            | Record the <b>date of assessment</b> in the <b>DD/MMM/YYYY</b> format. A complete date is required. |                          |          |          |
|   |   | Physical Well-Being (P   | WB)      |          |
| GP1   | Select the <b>option</b> from the drop-down list:   |                          |          |          |
|   | • 0   | •                        | 2        | • 4      |
|   | • 1   | •                        | 3        | Not Done |
| GP2   | Select the  | option from the drop-dow | ın list: |          |
|   | • 0   | •                        | 2        | • 4      |
|   | • 1   | •                        | 3        | Not Done |
| GP3   | Select the  | option from the drop-dow | ın list: |          |
|   | • 0   | •                        | 2        | • 4      |
|   | • 1   | •                        | 3        | Not Done |
| GP4 Select the option from the drop-down list |   | ın list:                 |          |          |
|   | • 0   | •                        | 2        | • 4      |
|   | • 1   | •                        | 3        | Not Done |
| GP5   | Select the <b>option</b> from the drop-down list:   |                          |          |          |
|   | • 0   | •                        | 2        | • 4      |
|   | • 1   | •                        | 3        | Not Done |
| GP6   | Select the <b>option</b> from the drop-down list:   |                          |          |          |
|   | • 0   | •                        | 2        | • 4      |
|   | • 1   | •                        | 3        | Not Done |
| GP7   | Select the <b>option</b> from the drop-down list:   |                          |          |          |
|   | • 0   | •                        | 2        | • 4      |
|   | • 1   | •                        | 3        | Not Done |
|   |   |                          |          |          |

## Social/Family Well-Being (SWB)

| GS1                                    | Select the <b>option</b> from the drop-down list: |                 |                              |  |
|--|---|-----------------|------------------------------|--|
|  | • 0   | • 2             | • 4                          |  |
|  | • 1   | • 3             | Not Done                     |  |
| GS2                                    | Select the <b>option</b> from the                 | drop-down list: |                              |  |
|  | • 0   | • 2             | • 4                          |  |
|  | • 1   | • 3             | Not Done                     |  |
| GS3                                    | Select the <b>option</b> from the drop-down list: |                 |                              |  |
|  | • 0   | • 2             | • 4                          |  |
|  | • 1   | • 3             | Not Done                     |  |
| GS4                                    | Select the <b>option</b> from the drop-down list: |                 |                              |  |
|  | • 0   | • 2             | • 4                          |  |
|  | • 1   | • 3             | Not Done                     |  |
| GS5                                    | Select the <b>option</b> from the drop-down list: |                 |                              |  |
|  | • 0   | • 2             | • 4                          |  |
|  | • 1   | • 3             | <ul> <li>Not Done</li> </ul> |  |
| GS6 Select the option from the drop-de |   | drop-down list: |                              |  |
|  | • 0   | • 2             | • 4                          |  |
|  | • 1   | • 3             | <ul> <li>Not Done</li> </ul> |  |
| GS7                                    | Select the <b>option</b> from the drop-down list: |                 |                              |  |
|  | • 0   | • 2             | • 4                          |  |
|  | • 1   | • 3             | <ul> <li>Not Done</li> </ul> |  |
|  |   |                 |                              |  |

## Emotional Well-Being (EWB)

| GE1 | Select the <b>option</b> from the drop-down list: |                    |                              |  |
|-----|---|--------------------|------------------------------|--|
|     | • 0   | • 2                | • 4                          |  |
|     | • 1   | • 3                | Not Done                     |  |
| GE2 | Select the <b>option</b> from th                  | ne drop-down list: |                              |  |
|     | • 0   | • 2                | • 4                          |  |
|     | • 1   | • 3                | Not Done                     |  |
| GE3 | Select the <b>option</b> from the drop-down list: |                    |                              |  |
|     | • 0   | • 2                | • 4                          |  |
|     | • 1   | • 3                | Not Done                     |  |
| GE4 | Select the <b>option</b> from the drop-down list: |                    |                              |  |
|     | • 0   | • 2                | • 4                          |  |
|     | • 1   | • 3                | <ul> <li>Not Done</li> </ul> |  |
| GE5 | Select the <b>option</b> from th                  | ne drop-down list: |                              |  |
|     | • 0   | • 2                | • 4                          |  |
|     | • 1   | • 3                | <ul> <li>Not Done</li> </ul> |  |
| GE6 | Select the <b>option</b> from the drop-down list: |                    |                              |  |
|     | • 0   | • 2                | • 4                          |  |
|     | • 1   | • 3                | <ul> <li>Not Done</li> </ul> |  |

## Functional Well-Being (FWB)

| GF1 | Select the <b>option</b> from the drop-down list: |   |                              |  |
|-----|---|---|------------------------------|--|
|     | • 0   | • 2   | • 4                          |  |
|     | • 1   | • 3   | Not Done                     |  |
| GF2 | Select the <b>option</b> from the drop-down list: |   |                              |  |
|     | • 0   | • 2   | • 4                          |  |
|     | • 1   | • 3   | Not Done                     |  |
| GF3 | Select the <b>option</b> from the                 | he drop-down list:                                |                              |  |
|     | • 0   | • 2   | • 4                          |  |
|     | • 1   | • 3   | Not Done                     |  |
| GF4 | Select the <b>option</b> from the                 | Select the <b>option</b> from the drop-down list: |                              |  |
|     | • 0   | • 2   | • 4                          |  |
|     | • 1   | • 3   | Not Done                     |  |
| GF5 | Select the <b>option</b> from the drop-down list: |   |                              |  |
|     | • 0   | • 2   | • 4                          |  |
|     | • 1   | • 3   | <ul> <li>Not Done</li> </ul> |  |
| GF6 | Select the <b>option</b> from the drop-down list: |   |                              |  |
|     | • 0   | • 2   | • 4                          |  |
|     | • 1   | • 3   | <ul> <li>Not Done</li> </ul> |  |
| GF7 | Select the <b>option</b> from the drop-down list: |   |                              |  |
|     | • 0   | • 2   | • 4                          |  |
|     | • 1   | • 3   | <ul> <li>Not Done</li> </ul> |  |

## Fatigue Subscale (FS)

| HI7  | Select the <b>option</b> from the drop-down list: |             |                              |  |
|------|---|-------------|------------------------------|--|
|      | • 0   | • 2         | • 4                          |  |
|      | • 1   | • 3         | <ul> <li>Not Done</li> </ul> |  |
| HI12 | Select the <b>option</b> from the drop-           |             |                              |  |
|      | • 0   | • 2         | • 4                          |  |
|      | • 1   | • 3         | Not Done                     |  |
| An1  | Select the <b>option</b> from the drop-           | -down list: |                              |  |
|      | • 0   | • 2         | • 4                          |  |
|      | • 1   | • 3         | Not Done                     |  |
| An2  | Select the <b>option</b> from the drop-           |             |                              |  |
|      | • 0   | • 2         | • 4                          |  |
|      | • 1   | • 3         | Not Done                     |  |
| An3  | Select the <b>option</b> from the drop-           |             |                              |  |
|      | • 0   | • 2         | • 4                          |  |
|      | • 1   | • 3         | Not Done                     |  |
| An4  | Select the <b>option</b> from the drop-           | -down list: |                              |  |
|      | • 0   | • 2         | • 4                          |  |
|      | • 1   | • 3         | Not Done                     |  |
| An5  | Select the <b>option</b> from the drop-           | -down list: |                              |  |
|      | • 0   | • 2         | • 4                          |  |
|      | • 1   | • 3         | Not Done                     |  |
| An7  | Select the <b>option</b> from the drop-down list: |             |                              |  |
|      | • 0   | • 2         | • 4                          |  |
|      | • 1   | • 3         | Not Done                     |  |
| An8  | Select the <b>option</b> from the drop-           |             |                              |  |
|      | • 0   | • 2         | • 4                          |  |
|      | • 1   | • 3         | Not Done                     |  |

| An12 | Select the option from the                        | ne drop-down list: |                              |
|------|---|--------------------|------------------------------|
|      | • 0   | • 2                | • 4                          |
|      | • 1   | • 3                | Not Done                     |
| An14 | Select the <b>option</b> from the                 | ne drop-down list: |                              |
|      | • 0   | • 2                | • 4                          |
|      | • 1   | • 3                | Not Done                     |
| An15 | Select the <b>option</b> from the drop-down list: |                    |                              |
|      | • 0   | • 2                | • 4                          |
|      | • 1   | • 3                | Not Done                     |
| An16 | Select the <b>option</b> from the drop-down list: |                    |                              |
|      | • 0   | • 2                | • 4                          |
|      | • 1   | • 3                | <ul> <li>Not Done</li> </ul> |

## PHARMACOKINETIC BLOOD SAMPLES



Was the sample collected?

Select No or Yes to indicate if the sample was collected.

Record the collection date in the DD/MMM/YYYY format. A complete date is required.

Collection time (24-hour clock format. Record the collection time performed in the HH:MM 24-hour clock format. clock):

PK sample collected due to overdose.

Check the box if the PK sample collected due to overdose.

## **PBMC IMMUNOGENICITY**



Was a Cellular Immunogenicity PBMC sample collected? Select **No** or **Yes** to indicate if the **Cellular Immunogenicity PBMC sample** was collected.

**Collection date:** 

Record the **collection date** in the **DD/MMM/YYYY** format. A complete date is

required.

Collection time (24-hour clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

#### **SERUM ANTI-DRUG ANTIBODY**



Was an Anti-drug Antibody serum sample collected?

Select **No** or **Yes** to indicate if the **Anti-drug Antibody serum sample** was collected.


**Collection date:** 

Record the **collection date** in the **DD/MMM/YYYY** format. A complete date is required.

Collection time (24-hour clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

#### PLASMA/SERUM EXPLORATORY BIOMARKERS



Was an Exploratory
Biomarkers plasma sample
collected?

Select **No** or **Yes** to indicate if the **Exploratory Biomarkers plasma sample** was collected.

Collection date:

Record the **collection date** in the **DD/MMM/YYYY** format. A complete date is

required.

Note: This field is only enabled if "Was an Exploratory Biomarkers plasma sample

collected?" is "Yes"

Collection time (24-hour clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

Note: This field is only enabled if "Was an Exploratory Biomarkers plasma sample

collected?" is "Yes"

Was an Exploratory
Biomarkers serum sample
collected?

Select **No** or **Yes** to indicate if the **Exploratory Biomarkers serum sample** was collected.

Note: This field is visible at all visits except Screening visit

Collection date:

Record the **collection date** in the **DD/MMM/YYYY** format. A complete date is

required.

Note: This field is visible at all visits except Screening visit

Note: This field is only enabled if "Was an Exploratory Biomarkers serum sample

collected?" is "Yes"

Collection time (24-hour clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

Note: This field is visible at **all** visits **except Screening** visit

Note: This field is only enabled if "Was an Exploratory Biomarkers serum sample

collected?" is "Yes"

## PBMC EXPLORATORY BIOMARKERS



Were Exploratory
Biomarkers PBMC samples
collected?

Select **No** or **Yes** to indicate if the **Exploratory Biomarkers PBMC samples** were collected.

Collection date:

Record the **collection date** in the **DD/MMM/YYYY** format. A complete date is required.

Collection time (24-hour clock):

Record the **collection time** performed in the **HH:MM 24-hour clock** format.

## REPLICATION COMPETENT LENTIVIRUS

clock):



Were RCL PBMC samples
collected?

Select No or Yes to indicate if the RCL PBMC samples were collected.

Record the collection date in the DD/MMM/YYYY format. A complete date is required.

Collection time (24-hour Record the collection time performed in the HH:MM 24-hour clock format.

## **MRI ASSESSMENTS**



Was MRI assessed?

Select No or Yes to indicate if the MRI was assessed.

**Timepoint** 

Select the **timepoint** from the dropdown menu.

• Baseline

- 24 to 48 Weeks Post-Infusion
- 3 to 6 Weeks Post-Infusion
- Unscheduled
- 10 to 14 Weeks Post-Infusion

**Collection date:** 

Record the **collection date** in the **DD/MMM/YYYY** format. A complete date is required.


## **NEXT VISIT - PRE-TREATMENT**




Is the subject continuing to the Pre-Treatment/Pre-Infusion visit OR will the subject be reassessed for apheresis at a later date? Select Pre-Treatment/Pre-Infusion or Apheresis reassessment to indicate if the Pre-Treatment/Pre-Infusion visit OR will the subject be reassessed for apheresis at a later date.

#### SBT777101 ADMINISTRATION

SBT777101 Administration eCRF is only available for completion at W1D1 visit.



The first portion of the SBT777101 Administration eCRF is shown here. See subsequent parts on the following page(s).



Was SBT777101 administered?

Select No or Yes to indicate if the SBT777101 was administered.

Chain of Identity (COI) number

Record the Chain of Identity (COI) number in the field provided.

Administration location

Select the **location** of administration from the drop-down list:

- Hand
- Wrist
- Antecubital
- Leg
- Other

Note: If "Other" is selected, provide a response in the "If Administration location

other, specify:" field

Date of infusion

Record the date of infusion in the DD/MMM/YYYY format. A complete date is

required.

Time SBT777101 was removed from shipper:

Record the time SBT777101 was removed from shipper in the HH:MM 24-hour

clock format.

SBT777101 thaw date

Record the SBT777101 thaw date in the DD/MMM/YYYY format. A complete date is

required.

Time SBT777101 was put in water bath (24 hour clock)

Record the time SBT777101 was put in water bath in the HH:MM 24-hour clock

format.

Planned SBT777101 dose level

Select the planned SBT777101 dose level in from the drop-down list:

- Dose Level 1
- Dose Level 2
- Dose Level 3
- Other

Note: If "Other" is selected, provide a response in the "Specify other planned dose

level (Million, M)" field

Planned volume of SBT777101 administered (mL)

Record the planned volume of SBT777101 administered in milliliter (mL) in the field provided.

Actual volume of SBT777101 administered (ml)

Record the actual volume of SBT777101 administered in milliliter (mL) in the field

provided.

| If Actual volume differs from Planned volume, provide reason: | Provide the <b>reason</b> actual volume differs from planned volume in the field provided.   |
|---|--|
| Infusion start time (24hr clock)                              | Record the infusion start time in the HH:MM 24-hour clock format.  |
| Infusion end time (24hr clock)                                | Record the infusion end time in the HH:MM 24-hour clock format.  |
| Rate of infusion (mL/min)                                     | Record the rate of infusion in mL/min in the field provided.   |
| Was infusion interrupted?                                     | Select <b>No</b> or <b>Yes</b> to indicate if the <b>infusion</b> was interrupted.   |
| Time of interruption - 1 (24hr clock)                         | Record the <b>time of interruption - 1</b> in the <b>HH:MM 24-hour clock</b> format.  Note: This field is only enabled if "Was infusion interrupted?" is "Yes"   |
| Reason infusion interrupted<br>-1                             | Select the reason infusion interrupted -1 from the dropdown list:  • ADVERSE EVENT  • OTHER  Note: This field is only enabled if "Was infusion interrupted?" is "Yes"  Note: If "Adverse Event" is selected, provide an Adverse Event number in the "Primary AE # that caused interruption - 1" field  Note: If "Other" is selected, specify the reason in the "Specify reason for interruption - 1" field |
| Was infusion restarted after interruption -1?                 | Select <b>No</b> or <b>Yes</b> to indicate if the <b>infusion</b> was restarted after interruption -1.  Note: This field is only enabled if " <b>Was infusion interrupted?</b> " is " <b>Yes</b> "   |
| Time of restart - 1 (24hr clock)                              | Record the <b>time of restart - 1</b> in the <b>HH:MM 24-hour clock</b> format.  Note: This field is only enabled if "Was infusion restarted after interruption -1?" is "Yes"  |
| Rate of infusion after interruption - 1 (mL/min)              | Record the <b>rate of infusion after interruption - 1</b> in <b>mL/min</b> in the field provided.  Note: This field is only enabled if "Was infusion restarted after interruption -1?" is "Yes"  |

Was infusion interrupted a second time?

Select **No** or **Yes** to indicate if the **infusion** was interrupted a second time.

Time of interruption - 2 (24hr clock)

Record the **time of interruption - 2** in the **HH:MM 24-hour clock** format.

Note: This field is only enabled if "Was infusion interrupted a second time?" is "Yes"

Reason infusion interrupted -2

Select the **reason infusion interrupted -2** from the dropdown list:

- ADVERSE EVENT
- OTHER

Note: This field is only enabled if "Was infusion interrupted a second time?" is "Yes"

Note: If "Adverse Event" is selected, provide an Adverse Event number in the "Primary AE # that caused interruption - 2" field

Note: If "Other" is selected, specify the reason in the "Specify reason for interruption - 2" field

Was infusion restarted after interruption -2?

Select **No** or **Yes** to indicate if the **infusion** was restarted after interruption -2. Note: This field is only enabled if "**Was infusion interrupted a second time?**" is "**Yes**"

Time of restart - 2 (24hr clock)

interruption - 2 (mL/min)

Record the time of restart - 2 in the HH:MM 24-hour clock format.

Note: This field is only enabled if "Was infusion restarted after interruption -2?" is "Yes"

Rate of infusion after

Record the **rate of infusion after interruption - 2** in **mL/min** in the field provided.


Note: This field is only enabled if "Was infusion restarted after interruption -2?" is "Yes"

## **NEXT VISIT**



Is the subject continuing to Select No or Yes to indicate if the subject is continuing to the next visit. the next visit?

#### GATE FORM - ANY AE/CM/PR



Did the subject experience any adverse events?

Select No or Yes.

If "Yes" is selected, an Adverse Events eCRF will appear for completion.

Were any of the adverse events related to CRS?

Select No or Yes.

 If "Yes" is selected, a CRS Signs and Symptoms eCRF will appear for completion.

Note: This field is only enabled if "Did the subject experience any adverse events?" is "Yes"

Were any of the adverse event related to Neurotoxicity?

Select No or Yes.

• If "Yes" is selected, a Neurotoxicity Signs and Symptoms eCRF will appear for completion.

Note: This field is only enabled if "Did the subject experience any adverse events?" is "Yes"

Were there any Infusion Related Reactions (IRR)?

Select No or Yes.

 If "Yes" is selected, an Infusion Related Reactions eCRF will appear for completion.

Note: This field is only enabled if "Did the subject experience any adverse events?" is "Yes"

Did the subject take any prior or concomitant medications?

Select No or Yes.


• If "Yes" is selected, a Prior & Concomitant Treatments/Medications eCRF will appear for completion.


Did the subject have any prior or concomitant procedures?

Select No or Yes.

• If "Yes" is selected, a Prior & Concomitant Procedures eCRF will appear for completion.


## **ADVERSE EVENTS**





Additional fields are required if the Adverse Event is Serious ("Was the adverse event serious?" is "Yes"), shown here.





All Adverse Events (AEs), regardless of seriousness or relationship to Investigational Product or study intervention, occurring from the time of first study drug administration until the final safety follow-up visit are to be recorded on the Adverse Events eCRF. This is a repeating form (multiple records can be added).

All Serious Adverse Events (SAEs) plus any AE that is the result of a protocol-specified procedure or intervention will be collected from the signing of the ICF until study drug administration. SAEs must be reported immediately (no later than 24 hours) on the Adverse Events eCRF. The Investigator will submit any updated SAE data to the Sponsor within 24 hours of it being available. Planned hospitalizations or procedures will not be considered as SAEs.

Medical occurrences that begin before study drug administration but after obtaining informed consent will be recorded as medical history/current medical conditions, not as AEs.

#### **Adverse Event:**

#### Provide the verbatim term of the adverse event.

- Record only one condition per record.
- The overall diagnosis should be reported rather than individual associated symptoms.
- If a specific diagnosis cannot be made, symptoms should be recorded as separate records.
- For intermittent or periodic events with the same CTCAE Grade, report the
  event only once with a qualifier that indicates that it is intermittent (e.g.,
  'intermittent headache') and select start and stop dates that show the overall
  duration of the event.
- If an event is an exacerbation of a pre-existing condition e.g. from physical examination, report the event with a qualifier that indicates that it is worsening (e.g., 'worsening headache'), and ensure that a corresponding Medical History record is completed for the pre-existing condition.
- If a clinically significant abnormality is noted at a physical examination, report the event as an Adverse Event.
- If an event is not a pre-existing condition that is recorded in Medical History eCRF, all changes in severity should be recorded as separate records.
   Examples include:
  - Day 5 Develops Grade 1 AE
    - → AE #1 is recorded in EDC
    - Day 12 Develops Grade 3 AE
      - → Grade 1 AE #1 ends with outcome of recovered, New Grade 3 AE #2 is recorded in EDC
  - Day 17 The event drops to Grade 2 AE
    - → Grade 3 AE #2 ends with outcome of recovered, New Grade 2 AE #3 recorded in EDC
  - Day 25 The event drops to Grade 1 AE and continues to the end of study
    - → Grade 2 AE #3 ends with outcome of recovered, New Grade 1 AE #4 recorded in EDC. Please note, AE #4 might have the same grade as AE #1. This is because the subject had no Medical History baseline to return to, so it is considered as a "new" AE.

- Medical/surgical procedures are not considered adverse events. If a surgical
  procedure occurs, ensure the associated indication is added as an adverse
  event or is a medical history condition.
- Death is an outcome and is not considered an adverse event. The cause of death should be recorded.
- Any condition that could have various locations or types should be specified.
   Examples include:
  - Anemia provide the type of anemia
  - Pain specify the location (e.g., left shoulder pain)
- Any condition which is ambiguous must include additional information.
   Example include:
  - Aches in hands Provide more detail (e.g., muscle aches, or Joint aches, or general)
  - Weakness Provide location or more detail (e.g., general weakness, or muscle weakness)
- Full stops, periods, and commas in the event term should be avoided.
- If CRS or Neurotoxicity is confirmed, record "CRS" or "Neurotoxicity" in the "Adverse event:" field. Then record the signs/symptoms of CRS or Neurotoxicity on the CRS or Neurotoxicity Signs and Symptoms eCRFs.

Start date: Record the start date of the AE in the DD/MMM/YYYY format. Start date should

be recorded as the date of first symptom onset. A complete date is required.

**Start Time:** Record the start time of the AE in the HH:MM 24-hour clock format.

Is this event a DLT? Indicate if the event is a DLT from the drop-down list:

- Yes, confirmed at SMC meeting
- Possibly, pending SMC meeting

Is this event related to CRS? Indicate if the **event is related to CRS?** from the drop-down list:

- No
- Yes
- **Possibly**

Is this event related to **Neurotoxicity/ICANS?** 

Indicate if the event is related to Neurotoxicity/ICANS? from the drop-down list:

- No
- Yes
- **Possibly**

Note: If an adverse event meets both CRS and Neurotoxicity/ICANS criteria, please enter as separate adverse events.

Infusion Related Reaction (IRR)

Check the box if the AE is Infusion Related Reaction.

Note: This applies to all AE's. If checked, please complete the Infusion Related

Reactions form.

Is this event an AESI? Indicate if the AE was an **AESI** by selecting from the drop-down list: **No** or **Yes**.

Outcome: Select the **outcome** of the AE from the drop-down list:

- Fatal
- Not Recovered or Not Resolved
- Recovered or Resolved
- Recovered or Resolved with Sequelae
- **Recovering or Resolving**
- Unknown

Note: If "Recovered or Resolved with Sequelae" is selected, describe sequelae in the "Describe sequelae:" field

End Date:

Record the end date of the AE in the DD/MMM/YYYY format. A complete date is

required.

Note: This field is only enabled if "Outcome" is "Recovered or Resolved",

"Recovered or Resolved with Sequelae", or "Fatal"

**End Time:** Record the end time of the AE in the **HH:MM 24-hour clock** format. Note:

Note: This field is only enabled if "Outcome" is "Recovered or Resolved",

"Recovered or Resolved with Sequelae", or "Fatal"

CTCAE Grade: Select the CTCAE Grade of the AE from the drop-down list:

Grade 1

• Grade 2

Grade 3

Grade 4

Grade 5

Note: If "Grade 5" is selected, please complete Death Details form under the

Summary folder.

ASTCT CRS Grade: Select the ASTCT CRS Grade of the AE from the drop-down list:

Grade 1

• Grade 2

Grade 3

Grade 4

Note: This field is only applicable if "Is this event related to CRS?" is "Yes" or "Possibly".

ASTCT ICANS Grade: Select the ASTCT ICANS Grade of the AE from the drop-down list:

Grade 1

• Grade 2

Grade 3

• Grade 4

Note: This field is only applicable if "Is this event related to

Neurotoxicity/ICANS?" is "Yes" or "Possibly".

Relationship to study treatment: Select the relationship to study treatment from the drop-down list:

Related

Possibly Related

Not Related

Action taken with study treatment:

Select the action taken with study treatment from the drop-down list:

DOSE NOT CHANGED

DOSE REDUCED

• DOSE INTERRUPTED

DRUG WITHDRAWN

NOT APPLICABLE

UNKNOWN

OTHER

Note: "Dose not changed" means no action is taken with study drug and is an applicable response only when the AE occurs during infusion on W1D1. For post infusion time events, action taken expected to be "Not Applicable.

Note: If "Other" is selected, specify in the "If Action taken with study treatment

is Other, specify:" field

If Action taken with study treatment is Dose Interrupted, was treatment reinitiated at the same rate or reduced rate? Select the rate the study treatment reinitiated from the drop-down list:

Same Rate

Reduced Rate

Note: This field is only enabled if "Action taken with study treatment:" is "DOSE INTERRUPTED"

Other Action Taken (Check all that apply)

Check the applicable box(es) for **other action taken** from the options provided:

- **Concomitant Medication**
- **Concomitant Procedure**
- Other, Specify

Note: If "Concomitant Medication" is selected, record the medication taken for this adverse event on the Prior & Concomitant Treatments/Medications eCRF Note: If "Concomitant Procedure" is selected, record the procedure performed for

this adverse event on the Prior & Concomitant Procedures eCRF

Note: If none of the provided options is applicable, specify in the "Other, Specify"

field

Was the event related to a trial procedure?

Indicate if the AE was related to a trial procedure by selecting from the drop-down

list: No or Yes.

Note: If "Yes" is selected, specify in the "If yes, specify" field

**Did this Adverse Event lead** to study discontinuation?

Indicate if the Adverse Event led to study discontinuation by selecting from the

drop-down list: No or Yes.

Note: This field is required for all AEs

Note: If "Yes" is selected, complete the Early Termination/End of Study eCRF

Was the adverse event serious?

Select No or Yes.

Note: If "Yes" is selected, the serious criteria fields below will be enabled for completion for the serious adverse event and an email alert will also be sent to the safety team when the form is saved.

Congenital anomaly or birth defect:

Indicate if the serious AE is a congenital anomaly or birth defect by selecting from

the drop-down list: No or Yes.

Persistent or significant disability:

Death:

Indicate if the serious AE results in persistent or significant disability by selecting from the drop-down list: No or Yes.

Indicate if the serious AE results in death by selecting from the drop-down list: No or

Yes.

Note: If "Yes" is selected, complete the Death Details CRF

Was an autopsy performed?

Indicate if an autopsy was performed by selecting from the drop-down list: No or Yes.

Note: This field is only enabled if "Death:" is "Yes"

Inpatient hospitalization or prolongation of existing hospitalization:

Indicate if the serious AE results in inpatient hospitalization or prolongs the existing hospitalization by selecting from the drop-down list: No or Yes.

Date of admission to hospital:

Record the date of hospital admission in the DD/MMM/YYYY format. A complete date is required.

Note: This field is only enabled if "Inpatient hospitalization or prolongation of

existing hospitalization:" is "Yes"

Date of discharge from

hospital:

Record the date of hospital discharge in the DD/MMM/YYYY format. A complete

date is required.

Note: This field is only enabled if "Inpatient hospitalization or prolongation of

existing hospitalization:" is "Yes"

**Life threatening:** Indicate if the serious AE is a **life-threatening** event by selecting from the drop-down

list: No or Yes.

Other medically important

event:

Indicate if the serious AE is other medically important event by selecting from the

drop-down list: No or Yes.

Other possible causes of the

event (If applicable):

If applicable, record any **other possible causes** of the serious AE in the text box

provided.

Describe the event (e.g., symptoms, treatment

course):

Describe the serious AE (symptoms, treatment, course, etc.) in the text box

provided.

## **CRS SIGNS AND SYMPTOMS**

This is a repeating form (multiple records can be added).



## CRS SIGNS AND SYMPTOMS (CONTINUED)

**Associated Adverse Event** 

Record the associated adverse event #1 number in field provided

#1:

**Associated Adverse Event** 

#2:

Record the associated adverse event #2 number in field provided

Associated Adverse Event #3:

Record the associated adverse event #3 number in field provided

Sign or Symptom of CRS

Select the sign or symptom of CRS from the drop-down list:

- Fever
- Hypotension
- Hypoxia
- Other

Note: If "Other" is selected, provide a response in the "If Sign or Symptom of CRS is Other, specify" field

Fever - max temperature recorded greater than or equal to 38 °C?

Select No or Yes to indicate if the max temperature recorded greater than or equal to 38 °C.

Note: This field is only enabled if "Sign or Symptom of CRS" is "Fever"

Hypotension - Vasopressor(s) required?

Select the **option** regarding vasopressor(s) required from the drop-down list:

- None
- Yes, a vasopressor with or without vasopressin
- Yes, multiple vasopressors (excluding vasopressin)

Note: This field is only enabled if "Sign or Symptom of CRS" is "Hypotension"

Hypoxia - Action(s) required?


Select the **option** regarding action(s) required from the drop-down list:

- None
- Low-flow nasal cannula or blow-by
- High-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask
- Positive pressure

Note: This field is only enabled if "Sign or Symptom of CRS" is "Hypoxia"

## **NEUROTOXICITY/ICANS SIGNS AND SYMPTOMS**

This is a repeating form (multiple records can be added).



Associated Adverse Event #1:

Record the associated adverse event #1 number in field provided

Associated Adverse Event #2:

Record the associated adverse event #2 number in field provided

Associated Adverse Event #3:

Record the associated adverse event #3 number in field provided

## NEUROTOXICITY/ICANS SIGNS AND SYMPTOMS (CONTINUED)

#### Sign and Symptom of Neurotoxicity

Select the sign or symptom of Neurotoxicity from the drop-down list:

- Seizures
- Tremor
- Elevated ICP Cerebral edema
- Depressed level of consciousness
- Myoclonus
- Hemi or Paraparesis
- Other

Note: If "Other" is selected, provide a response in the "If Sign or Symptom of Neurotoxicity is Other, specify" field

## Depressed level of consciousness Assessment

Select the **option** regarding depressed level of consciousness assessment from the drop-down list:

- Awakens spontaneously
- Awakens to voice
- Awakens only to tactile stimulus
- Unarousable or requires vigorous or repetitive tactile stimuli to around
- Stupor or Coma

Note: This field is only enabled if "Sign and Symptom of Neurotoxicity" is "Depressed level of consciousness"

#### **Seizure Assessment**

Select the **option** regarding seizure assessment from the drop-down list:

- Clinical seizure that resolved rapidly
- Nonconvulsive seizures on EEG that resolve with intervention
- Life-threatening prolonged seizure>5 min
- Repetitive clinical or electrical seizures without return to baseline in between

Note: This field is only enabled if "Sign and Symptom of Neurotoxicity" is "Seizures"

## Elevated ICP and/or Cerebral edema Assessment

Select the **option** regarding elevated ICP and/or cerebral edema assessment from the drop-down list:

- Focal-Local edema on neuroimaging
- Diffuse cerebral edema on neuroimaging
- Decerebrate or decorticate posturing
- Cranial nerve VI palsy
- Papilledema
- Cushing's triad

Note: This field is only enabled if "Sign and Symptom of Neurotoxicity" is "Elevated ICP - Cerebral edema"

#### INFUSION RELATED REACTIONS

This is a repeating form (multiple records can be added).



Associated Adverse Event #: Record the associated adverse event number in field provided

Total estimated volume of SBT777101 administered at onset of this Infusion Related Reaction:

Record the **total estimated volume of SBT777101 administered** at the onset of this IRR in the field provided.

Was a pre-treatment given?

Select **No** or **Yes** to indicate if a **pre-treatment** was given.

Concomitant Medication # in EDC:

Record the **associated concomitant medication number** in field provided <u>Note</u>: This field is only enabled if "Was a pre-treatment given?" = "Yes"

Was a blood sample collected for the IRR?

Select **No** or **Yes** to indicate if a **blood sample** was collected for the IRR.

Date of blood sample collection:

Record the **date of collection** in the **DD/MMM/YYYY** format. A complete date is required.

Note: This field is only enabled if "Was a blood sample collected?" = "Yes"

Time of blood sample collection:

Record the **time of collection** in the **HH:MM 24-hour clock** format.

Note: This field is only enabled if "Was a blood sample collected?" is "Yes"

#### PRIOR & CONCOMITANT TREATMENTS/MEDICATIONS

This is a repeating form (multiple records can be added).



#### PRIOR & CONCOMITANT TREATMENTS/MEDICATIONS (CONTINUED)

General medications taken by the subject within 4 weeks prior to screening to the end of the study/early termination visit should be recorded. Pain medications and corticosteroids used to manage signs and symptoms of RA are considered general medications.

Medication:

Provide the name of the **medication** in the field provided.

- Please do not record strength in the medication field
- Record only one medication per record.
- If the same medication has multiple start/stop dates, please record each as its own record, e.g. prednisone either with multiple start/stop dates and/or changes in dose.
- Please record each administration of Rituximab as a unique entry for any administration completed after the subject signs consent and not as a single ongoing entry.
- Please list any RA medications initiated after signing consent as a conmed and not RA Med history.
- For combination medications:
  - Do not split into separate entries.
  - Record the brand name with the generic name in parentheses, if available. (E.g., Bactrim (sulfamethoxazole + trimethoprim))
- For multi-ingredient products, supplements, and store-brand medications:
  - Record active ingredients in parentheses next to product name. (E.g., Robitussin (guaifenesin/dextromethorphan HBr)
- Full stops, periods, and commas in the medication name should be avoided.

Indication:

Provide the **indication** in the field provided.

- Ensure the indication reflects the specific condition/diagnosis and not the type of drug.
- If medications are given to treat a medical history condition or adverse event, ensure the condition is recorded on the Medical History or Adverse Event eCRF.
- Medications taken as a preventative measure and not for general health or a
  pre-existing or current condition should include that information with the
  indication (e.g., 'infection prophylaxis').

## PRIOR & CONCOMITANT TREATMENTS/MEDICATIONS (CONTINUED)

Reason (select all that apply):

Select all applicable box(es) regarding the **reason for the treatment/medication** from the drop-down list:

- Adverse Event
- Medical History
- Prophylaxis
- Procedure
- Rheumatoid Arthritis Treatment
- Other

Note: If "Adverse Event" is selected, record the corresponding primary adverse event number in the "Primary Adverse Event # indicated (record the primary AE associated):" field

Note: If "Medical History" is selected, record the corresponding primary adverse event number in the "Primary Medical History # indicated (record the primary MH associated):" field

<u>Note:</u> If "Procedure" is selected, record the corresponding primary adverse event number in the "Primary Procedure # indicated (record the primary procedure associated):" field

Note: If "Other" is selected, specify the reason in the "Reason Other, specify:" field

Dose:

Provide a numeric **dose** of the medication taken.

- For combination drugs, enter the number of tablets/capsules
- If the dose is a range (e.g., Insulin use of 2-10 units), the upper end of the range should be entered (e.g., 10 units).
- If a medication's dose changes, create a new record for each dose level.

Unit:

Select the unit of the dose taken from the drop-down list:

| • | APPLICATION | • | mg   | • | <b>TABLET</b> |
|---|-------------|---|------|---|---------------|
| • | CAPSULE     | • | mL   | • | U             |
| • | DROP        | • | mL/h | • | U/kg          |
| • | g           | • | mmol | • | U/kg/day      |
| • | IU          | • | oz   | • | ug            |
| • | mEq         | • | PUFF | • | OTHER         |

Note: If "Other" is selected, specify in the "Unit specify:" field

Frequency:

Select the **frequency** of the treatment/medication from the drop-down list:

- BID (twice per day)
- CONTINUOUS
- EVERY WEEK
- ONCE
- PRN (as needed)
- QD (once per day)

- QID (4 times per day)
- QOD (every other day)
- TID (three times a day)
- Unknown
- Other

Note: If "Other" is selected, provide a response in the "Frequency specify:" field

# PRIOR & CONCOMITANT TREATMENTS/MEDICATIONS (CONTINUED)

**Route:** Select the **route** of the treatment/medication from the drop-down list:

AURICULAR (OTIC)

• ENTERAL

EPIDURAL

INTRA-ARTICULAR

INTRADERMAL

INTERACTIONS

INTRAMUSCULARINTRAOCULAR

INTRATHECAL

INTRAVENOUS

NASAL

NASOGASTRIC

OPHTHALMIC

ORAL

RECTAL

• RESPIRATORY (INHALATION)

SUBCUTANEOUS

TOPICAL

• TRANSDERMAL

VAGINAL

OTHER

Note: If "Other" is selected, provide a response in the "Route specify:" field

Start date: Record the start date of the treatment/medication in the DD/MMM/YYYY format.

Note: A year is required for start date. "Unknown" is an available selection for Day

and Month

Ongoing? Select No or Yes to indicate if the treatment/medication is currently ongoing.

Note: If the treatment/medication changes/updates from ongoing to resolved during

the study, update this field accordingly

End date: Record the end date of the treatment/medication in the DD/MMM/YYYY format.

Note: This field is only enabled if "Ongoing?" is "No". A year is required for end date.

"Unknown" is an available selection for Day and Month

#### PRIOR & CONCOMITANT PROCEDURES

This is a repeating form (multiple records can be added).

| Subject                                  | : <b>101, 200</b> Event: <b>Summary</b> | Form: Prior & Concomitant Procedures |  |
|--|---|--------------------------------------|--|
| Procedure:                               |   |                                      |  |
|  |   |                                      |  |
| Reason for Procedure:                    |   |                                      |  |
| Select 🔻 🔊 🖺                             |   |                                      |  |
| If Adverse Event, specify primary AE#:   |   |                                      |  |
| <b>.</b>                                 |   |                                      |  |
| If Medical History, specify primary MH#: |   |                                      |  |
| <b>.</b>                                 |   |                                      |  |
| If Other, specify:                       |   |                                      |  |
| <b>0</b> C                               |   |                                      |  |
| Start Date:                              |   |                                      |  |
| Day V Month V Year V 🗎 🤊 🗈               |   |                                      |  |
| End Date:                                |   |                                      |  |
| Day V Month V Year V 🗎 🔊 🗈               |   |                                      |  |
|  |   |                                      |  |
| + Add Another                            |   |                                      |  |

**Procedure:** 

Record the **procedure** in the text box provided.

Reason for Procedure:

Select the **reason for procedure** from the drop-down list:

- ADVERSE EVENT
- MEDICAL HISTORY
- TREATMENT OF RA
- OTHER

Note: If "Adverse Event" is selected, record the corresponding primary adverse

event number in the "If Adverse Event, specify primary AE#:" field
Note: If "Medical History" is selected, record the corresponding primary adverse

event number in the "If Medical History, specify primary MH#:" field

Note: For RA medications, select "Treatment of RA" as the Reason for Procedure.

Do not select Medical History.

Note: If "Other" is selected, specify the reason in the "If Other, specify:" field

Start date:

Record the **start date** of the treatment/medication in the **DD/MMM/YYYY** format.

Note: A year is required for start date. "**Unknown**" is an available selection for Day and Month

End date:

Record the **end date** of the treatment/medication in the **DD/MMM/YYYY** format.

Note: A year is required for end date. "**Unknown**" is an available selection for Day and Month

#### **GATE-MARKERS**




Were Markers of Inflammation assessed?

Select No or Yes to indicate if the markers of inflammation was assessed.

• If "Yes" is selected, a Markers of Inflammation eCRF will appear for completion.

# **MARKERS OF INFLAMMATION**

This is a repeating form (multiple records can be added).



For the sake of brevity, the screenshot for this form only shows other markers tested – Marker 1. Other Marker #2-5 fields are comparable to the other Marker 1 image.

# MARKERS OF INFLAMMATION (CONTINUED)

Ferritin (mcg/L)

IL-6 (pg/ml)

Time point for sample Select the time point for sample collection from the drop-down list: collection: **Pre-Treatment Adverse Event** Date of sample collection Record the date of sample collection in the DD/MMM/YYYY format. A complete date is required. Time of sample collection Record the time of sample collection performed in the HH:MM 24-hour clock (24 hour clock) format. Record the primary suspected adverse event of infection or CRS number in the Primary suspected adverse event of infection or CRS # field provided. Interferon Gamma (pg/mL) Record the Interferon Gamma in pg/mL in the field provided.

Record the **Ferritin** in **mcg/L** in the field provided.

Record the **IL-6** in **pg/mL** in the field provided.

## MARKERS OF INFLAMMATION (CONTINUED)

#### Any other markers tested?

Select No or Yes to indicate if any other markers was tested.

Note: If "No" is selected, no additional fields to record other markers will appear. If "Yes" is selected, the "Marker 1 - Record Marker Name", "Result", and "Unit" fields will appear. Up to five (5) other markers can be recorded per Markers of Inflammation eCRF. Data may be recorded in the subsequent Other Marker #2-5 fields that appear. These subsequent Other Marker #2-5 fields should be completed in the same manner as the Other Marker #1 fields.

Marker 1 - Record Marker Name

Record the marker 1 name in the field provided.

Note: This field is only enabled if "Any other markers tested?" is "Yes"

Result

Record the result of marker 1 in the field provided.

Note: This field is only enabled if "Any other markers tested?" is "Yes"

Unit:

Select the corresponding **unit** for the result from the drop down-list:

% L/L /hpf M/mcL /lpf mcg/dL cc/min mcIU cells/mcL mcIU/mL pmol/L cells/uL mcm<sup>3</sup> E.U./dL mcmol/L Ehr U U/mL mEq/L Ehr U/dL mg/dL uIU/mL Eq/L mg/L fL mIU/mL x 10<sup>3</sup>/mcL g/dL mL/min x 10^6/mm^3

IU/L mmol/L IU/mL mU/L K/mm<sup>3</sup> ng/dL K/mcL

mL/min/1.73m^2

g/L

ng/mL nmol/L

pg/mL

seconds

x 10<sup>3</sup>/mm<sup>3</sup>


x 10^6/mcL

No Unit

 x 10<sup>9</sup>/L x 10<sup>12</sup>/L

pg

U/L



Date of death Record the date of death in the DD/MMM/YYYY format. A complete date is

required.

Date of death data collection Record the date of death data collection in the DD/MMM/YYYY format. A complete

date is required.

Primary cause of death Select the primary cause of death from the drop-down list:

Adverse Event

Other


Note: If "Adverse Event" is selected, record the corresponding primary adverse event number in the "Specify Primary Adverse Event sequence number" field Note: If "Other" is selected, specify the primary cause of death in the "If Other,

specify" field

Was an autopsy performed? Select No or Yes to indicate if an autopsy was performed.

#### **RECONSENT**

This is a repeating form (multiple records can be added).



**Date of reconsent:** Record the **date of reconsent** in the **DD/MMM/YYYY** format. A complete date is required.

Protocol version which the subject reconsented under?

Select the **protocol version** the subject the subject reconsented under from the drop-down list:

• 5.0

• 8.0

• 6.0

• 9.0

7.0

• 10.0

#### **EARLY TERMINATION/END OF STUDY**

Early Termination/End of Study eCRF is found in Summary folder.



Date of Early Termination/Study completion: Record the date of early termination/study completion in the DD/MMM/YYYY format. A complete date is required.

Did the subject complete all periods of the study including the final safety follow-up visit?

Select No or Yes to indicate if the subject completed all periods of the study including the final safety follow-up visit.

# **EARLY TERMINATION/END OF STUDY (CONTINUED)**

**Primary reason:** 

Select the primary reason from the drop-down list:

- ADVERSE EVENT
- DEATH
- FAILURE TO MEET TREATMENT ELIGIBILITY REQUIREMENTS
- LOST TO FOLLOW-UP
- MANUFACTURING FAILURE
- PHYSICIAN DECISION
- PROTOCOL DEVIATION
- STUDY TERMINATED BY SPONSOR
- WITHDRAWAL BY SUBJECT
- OTHER

Note: This field is only enabled if "Did the subject complete all periods of the study including the final safety follow-up visit?" is "No"

Note: If "Other" is selected, specify the reason in the "Specify reason:" field

Did the subject consent to enroll in the long-term follow-up trial?

Select **No** or **Yes** to indicate if the **subject consented to enroll in the long-term follow-up trial**.

If the subject consented for future research of Blood, CAR Treg Cells, Synovial Tissue, and Synovial Fluid Samples, has there been a change to that response? Select No or Yes to indicate if there has been a change to subject consented for future research of Blood, CAR Treg Cells, Synovial Tissue, and Synovial Fluid Samples.

Note: This field is only enabled if "Primary reason:" is "Withdrawal by Subject"